<html lang="en" class="pb-page js" data-request-id="94d67cdc554fa432-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d67cdc554fa432-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/QRjtAhsbm1D2Fq_YsTGt6TBk9KAK6iMSXGeFr2qLMZweh-7RssEhwhjMcajd_Mj9wJ6djmL9EtQFb9fogTWULw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d67cdc554fa432-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.9137775850045045"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease">
<meta name="topics" content="Tuberculosis|Bacterial Infections|Infectious Disease General|Global Health">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2033400","title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","category":"Research","type":"Original Article","topics":"Tuberculosis|Bacterial Infections|Infectious Disease General|Global Health","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-05-06T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Tuberculosis|Bacterial Infections|Infectious Disease General|Global Health\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2033400","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","doi":"10.1056/NEJMdo006050","issueDate":"2021-05-06T00:00Z","age":"6Months-1990","isFree":"n","topics":"Tuberculosis|Bacterial Infections|Infectious Disease General|Global Health","viewType":"Full","specialties":"Infectious Disease"},{"type":"Quick Take","title":"Four-Month Rifapentine-Based Regimens with or without Moxifloxacin for Tuberculosis","doi":"10.1056/NEJMdo006005","issueDate":"2021-05-06T00:00Z","age":"6Months-1990","isFree":"n","topics":"Tuberculosis|Bacterial Infections|Infectious Disease General|Global Health","viewType":"Full","specialties":"Infectious Disease"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d67cdc554fa432-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"><meta name="dc.Creator" content="Susan E. Dorman"><meta name="dc.Creator" content="Payam Nahid"><meta name="dc.Creator" content="Ekaterina V. Kurbatova"><meta name="dc.Creator" content="Patrick P.J. Phillips"><meta name="dc.Creator" content="Kia Bryant"><meta name="dc.Creator" content="Kelly E. Dooley"><meta name="dc.Creator" content="Melissa Engle"><meta name="dc.Creator" content="Stefan V. Goldberg"><meta name="dc.Creator" content="Ha T.T. Phan"><meta name="dc.Creator" content="James Hakim"><meta name="dc.Creator" content="John L. Johnson"><meta name="dc.Creator" content="Madeleine Lourens"><meta name="dc.Creator" content="Neil A. Martinson"><meta name="dc.Creator" content="Grace Muzanyi"><meta name="dc.Creator" content="Kim Narunsky"><meta name="dc.Creator" content="Sandy Nerette"><meta name="dc.Creator" content="Nhung V. Nguyen"><meta name="dc.Creator" content="Thuong H. Pham"><meta name="dc.Creator" content="Samuel Pierre"><meta name="dc.Creator" content="Anne E. Purfield"><meta name="dc.Creator" content="Wadzanai Samaneka"><meta name="dc.Creator" content="Radojka M. Savic"><meta name="dc.Creator" content="Ian Sanne"><meta name="dc.Creator" content="Nigel A. Scott"><meta name="dc.Creator" content="Justin Shenje"><meta name="dc.Creator" content="Erin Sizemore"><meta name="dc.Creator" content="Andrew Vernon"><meta name="dc.Creator" content="Ziyaad Waja"><meta name="dc.Creator" content="Marc Weiner"><meta name="dc.Creator" content="Susan Swindells"><meta name="dc.Creator" content="Richard E. Chaisson"><meta name="dc.Description" content="Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.In an open-label, phase 3, randomized,..."><meta name="Description" content="Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.In an open-label, phase 3, randomized,..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-05-06"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2033400"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202105063841808"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2104499"><meta name="dc.Relation" content="YXQYoa2033400"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2033400">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2033400">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2033400">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM">
        <meta property="og:title" content="Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2033400">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/1a13f36b-26f4-4027-a8a6-75d141538758/nejmoa2033400_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/1a13f36b-26f4-4027-a8a6-75d141538758/nejmoa2033400_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Rifapentine-based regimens have potent antimycobacterial activity that may allow for
a shorter course in patients with drug-susceptible pulmonary tuberculosis. In an open-label,
phase 3, randomized...">
        <meta name="twitter:description" content="Rifapentine-based regimens have potent antimycobacterial activity that may allow for
a shorter course in patients with drug-susceptible pulmonary tuberculosis. In an open-label,
phase 3, randomized...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2033400">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2033400">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2021.384.issue-18;page:string:Article/Chapter View;article:article:doi\:10.1056/NEJMoa2033400;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033400" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033400" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033400" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2033400" class="inputDoi"><input type="hidden" value="S.E. Dorman and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1705-1718" class="inputCitation"><input type="hidden" value="05-05-2021" class="inputEPubDate"><input type="hidden" value="May 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d67cdc554fa432-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Susan E.</span> <span property="familyName">Dorman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Payam</span> <span property="familyName">Nahid</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2811-1311" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2811-1311</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ekaterina V.</span> <span property="familyName">Kurbatova</span>, <span property="honorificSuffix">M.D., Ph.D., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patrick P.J.</span> <span property="familyName">Phillips</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kia</span> <span property="familyName">Bryant</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kelly E.</span> <span property="familyName">Dooley</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Melissa</span> <span property="familyName">Engle</span>, <span property="honorificSuffix">C.R.T., C.C.R.C.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+24</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stefan V.</span> <span property="familyName">Goldberg</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ha T.T.</span> <span property="familyName">Phan</span>, <span property="honorificSuffix">Dr.P.H., M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James</span> <span property="familyName">Hakim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John L.</span> <span property="familyName">Johnson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Madeleine</span> <span property="familyName">Lourens</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Neil A.</span> <span property="familyName">Martinson</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Grace</span> <span property="familyName">Muzanyi</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kim</span> <span property="familyName">Narunsky</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandy</span> <span property="familyName">Nerette</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nhung V.</span> <span property="familyName">Nguyen</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thuong H.</span> <span property="familyName">Pham</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Samuel</span> <span property="familyName">Pierre</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anne E.</span> <span property="familyName">Purfield</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wadzanai</span> <span property="familyName">Samaneka</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Radojka M.</span> <span property="familyName">Savic</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ian</span> <span property="familyName">Sanne</span>, <span property="honorificSuffix">M.B., B.Ch., D.T.M.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nigel A.</span> <span property="familyName">Scott</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Justin</span> <span property="familyName">Shenje</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Erin</span> <span property="familyName">Sizemore</span>, <span property="honorificSuffix">M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Vernon</span>, <span property="honorificSuffix">M.D., M.H.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ziyaad</span> <span property="familyName">Waja</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marc</span> <span property="familyName">Weiner</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susan</span> <span property="familyName">Swindells</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Richard E.</span> <span property="familyName">Chaisson</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium</span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-24</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 5, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1705</span>-<span property="pageEnd">1718</span></div><div class="doi">DOI: 10.1056/NEJMoa2033400</div><div class="core-enumeration"><a href="/toc/nejm/384/18"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">18</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSusan%2BE.%2BDorman%252C%2BPayam%2BNahid%252C%2BEkaterina%2BV.%2BKurbatova%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D18%26contentID%3D10.1056%252FNEJMoa2033400%26title%3DFour-Month%2BRifapentine%2BRegimens%2Bwith%2Bor%2Bwithout%2BMoxifloxacin%2Bfor%2BTuberculosis%26publicationDate%3D05%252F06%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2033400" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSusan%2BE.%2BDorman%252C%2BPayam%2BNahid%252C%2BEkaterina%2BV.%2BKurbatova%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D18%26contentID%3D10.1056%252FNEJMoa2033400%26title%3DFour-Month%2BRifapentine%2BRegimens%2Bwith%2Bor%2Bwithout%2BMoxifloxacin%2Bfor%2BTuberculosis%26publicationDate%3D05%252F06%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/1ff120d5-d4b1-4056-ab76-bb0a599ef337/nejmoa2033400.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2033400.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033400" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2033400" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033400.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmonary tuberculosis from 13 countries, we compared two 4-month rifapentine-based regimens with a standard 6-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol (control) using a noninferiority margin of 6.6 percentage points. In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival free of tuberculosis at 12 months.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f0.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/1a13f36b-26f4-4027-a8a6-75d141538758/assets/images/large/nejmoa2033400_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Among 2516 participants who had undergone randomization, 2343 had a culture positive for <i>Mycobacterium tuberculosis</i> that was not resistant to isoniazid, rifampin, or fluoroquinolones (microbiologically eligible population; 768 in the control group, 791 in the rifapentine–moxifloxacin group, and 784 in the rifapentine group), of whom 194 were coinfected with human immunodeficiency virus and 1703 had cavitation on chest radiography. A total of 2234 participants could be assessed for the primary outcome (assessable population; 726 in the control group, 756 in the rifapentine–moxifloxacin group, and 752 in the rifapentine group). Rifapentine with moxifloxacin was noninferior to the control in the microbiologically eligible population (15.5% vs. 14.6% had an unfavorable outcome; difference, 1.0 percentage point; 95% confidence interval [CI], −2.6 to 4.5) and in the assessable population (11.6% vs. 9.6%; difference, 2.0 percentage points; 95% CI, −1.1 to 5.1). Noninferiority was shown in the secondary and sensitivity analyses. Rifapentine without moxifloxacin was not shown to be noninferior to the control in either population (17.7% vs. 14.6% with an unfavorable outcome in the microbiologically eligible population; difference, 3.0 percentage points [95% CI, −0.6 to 6.6]; and 14.2% vs. 9.6% in the assessable population; difference, 4.4 percentage points [95% CI, 1.2 to 7.7]). Adverse events of grade 3 or higher occurred during the on-treatment period in 19.3% of participants in the control group, 18.8% in the rifapentine–moxifloxacin group, and 14.3% in the rifapentine group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">The efficacy of a 4-month rifapentine-based regimen containing moxifloxacin was noninferior to the standard 6-month regimen in the treatment of tuberculosis. (Funded by the Centers for Disease Control and Prevention and others; Study 31/A5349 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02410772" target="_blank">NCT02410772</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006005/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/206a3a7e-67f4-475e-9dfd-f9e55400aa60/media/NEJMdo006005_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006005/full/" class="ng-do-media_item-title-link">Four-Month Rifapentine-Based Regimens with or without Moxifloxacin for Tuberculosis</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 48s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Highly potent treatment regimens in patients with tuberculosis could allow the treatment course to be shortened to less than the currently required 6 months, thereby facilitating improved adherence and potentially reducing adverse drug effects and costs.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3" href-manipulated="true">1-3</a></sup> As an antimicrobial class, rifamycins are a cornerstone of antituberculosis treatment because of their ability to sterilize lesions and provide a durable cure.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4" href-manipulated="true" aria-label="Reference 4">4</a></sup> Results of preclinical models of tuberculosis and phase 2 clinical trials show a relationship between exposure to rifamycins and reduction in bacillary burden.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7" id="body-ref-r7-1" href-manipulated="true">5-7</a></sup> Increasing exposure to rifamycins may be a promising strategy to shorten the course of tuberculosis treatment.</div><div role="paragraph">Rifapentine is a cyclopentyl derivative of rifampin, the most widely used rifamycin worldwide. Rifapentine has activity against <i>Mycobacterium tuberculosis</i>, and its longer half-life makes the drug an attractive option for increasing the duration of exposure to rifamycins while maintaining the once-daily dosing schedule that facilitates the completion of treatment.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup> Moxifloxacin is a fluoroquinolone with activity against <i>M. tuberculosis</i>.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">9-12</a></sup> The addition of moxifloxacin to other first-line antibiotics against tuberculosis, including rifampin, accelerates sputum-culture conversion to negative status early in the course of treatment but is insufficient to shorten therapy to 4 months.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r16 r17 r18" id="body-ref-r18" href-manipulated="true">13-18</a></sup> Combination treatment that includes both rifapentine and moxifloxacin was shown to be active in the murine model of tuberculosis and provided a stable cure after 3 months of treatment.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20" href-manipulated="true">19,20</a></sup> In phase 2 clinical trials, no obvious safety concerns were noted with the use of rifapentine during the first 8 weeks of combination chemotherapy for pulmonary tuberculosis, and increasing the pharmacokinetic exposure to rifapentine was shown to be associated with sputum sterilization at the time of completion of the intensive phase.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22-1" href-manipulated="true">21,22</a></sup></div><div role="paragraph">We conducted a phase 3 clinical trial to determine whether treatment regimens that included rifapentine, at a once-daily dose of 1200 mg, with or without moxifloxacin, at a once-daily dose of 400 mg, can provide a durable cure in participants with drug-susceptible pulmonary tuberculosis in 4 months, as compared with the standard 6-month regimen. Safety measures, including premature discontinuation of the assigned regimen for a reason other than microbiologic ineligibility, were also assessed and compared.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">The Tuberculosis Trials Consortium Study 31/AIDS Clinical Trials Group A5349 (Study 31/A5349) was an international, multicenter, randomized, open-label, phase 3, noninferiority trial conducted at sites of the Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium and the National Institutes of Health AIDS Clinical Trials Group. Full details of the design and implementation of the trial have been published previously<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-1" href-manipulated="true" aria-label="Reference 23">23</a></sup> and are provided in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org. The trial protocol was approved by the institutional review board at the CDC. An institutional review board or ethics committee at each participating trial site reviewed and approved the protocol and informed consent documents, or a trial site relied formally on the approval from the CDC. All the participants provided written informed consent.</div><div role="paragraph">Members of the protocol team from the Tuberculosis Trials Consortium and the AIDS Clinical Trials Group designed and implemented the trial and collected and analyzed the data. The protocol team included some of the authors. The first draft of the manuscript was written by the first and corresponding authors. No one who was not an author contributed to the writing of the manuscript. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. Sanofi provided rifapentine, rifampin, moxifloxacin, and all companion drugs, and a company representative participated on the protocol team. The commercial interests of Sanofi did not influence the trial design; the collection, analysis, or interpretation of the data; the preparation of the manuscript; or the decision to submit the manuscript for publication. The trial was conducted in accordance with the principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements.</div></section><section id="sec-1-2"><h3>Participants</h3><div role="paragraph">The participants were 12 years of age or older and had newly diagnosed pulmonary tuberculosis that was confirmed on culture to be susceptible to isoniazid, rifampin, and fluoroquinolones. Participants were required to have at least one sputum specimen that was positive for acid-fast bacilli on smear microscopy or positive for <i>M. tuberculosis</i> on a rapid nucleic acid amplification test (Xpert MTB/RIF, Cepheid), with a semiquantitative result of medium or high, which approximately matches the criteria for a positive smear.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25" href-manipulated="true">24,25</a></sup> Persons with human immunodeficiency virus (HIV) infection were required to have a CD4 T-cell count of at least 100 cells per cubic millimeter and were enrolled to evaluate drug–drug interactions between rifapentine, 1200 mg once daily, and efavirenz.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup> Full details of the criteria for eligibility are provided in the <a href="#ap1">protocol</a> and the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></section><section id="sec-1-3"><h3>Randomization and Treatment</h3><div role="paragraph">The participants were randomly assigned in a 1:1:1 ratio to one of three regimens with the use of a central Web-based system and the “big stick” design by Soares and Wu,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> with a maximum allowable imbalance of two (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). Randomization was stratified according to trial site, presence of cavitation on chest radiography at baseline, and HIV status. The control regimen involved 8 weeks of once-daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 18 weeks of once-daily rifampin and isoniazid.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-2" href-manipulated="true">1,2</a></sup> The rifapentine regimen involved 8 weeks of once-daily rifapentine, isoniazid, pyrazinamide, and ethambutol followed by 9 weeks of once-daily rifapentine and isoniazid. The rifapentine–moxifloxacin regimen involved 8 weeks of once-daily rifapentine, isoniazid, pyrazinamide, and moxifloxacin followed by 9 weeks of once-daily rifapentine, isoniazid, and moxifloxacin. Rifapentine was administered at a daily dose of 1200 mg, and moxifloxacin at a daily dose of 400 mg.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r22" id="body-ref-r22-2" href-manipulated="true">7,22</a></sup> Other drugs were administered at standard doses adjusted for body weight (Table S1).<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-3" href-manipulated="true" aria-label="Reference 1">1</a></sup> Because food affects the absorption of rifapentine and rifampin differently, rifapentine was administered within 1 hour after ingesting food, and rifampin was administered on an empty stomach.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r22 r27 r28" id="body-ref-r28" href-manipulated="true">1,22,27,28</a></sup> The medications in each regimen were administered 7 days per week, including at least 5 days of in-person directly observed therapy per week.</div></section><section id="sec-1-4"><h3>Trial Procedures</h3><div role="paragraph">The participants were monitored according to the schedule provided in Table S2. Sputum specimens were collected for mycobacterial cultures and blood samples for complete blood counts and biochemical analyses. Two sputum specimens were collected at all scheduled visits at or after week 17. Mycobacteriologic procedures across the trial-site laboratories were harmonized according to 20 key elements (Table S16).<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-3" href-manipulated="true" aria-label="Reference 23">23</a></sup> Smear microscopy and mycobacterial culture on liquid media (Mycobacteria Growth Indicator Tubes [MGIT] System, Becton Dickinson) and solid media were performed at designated trial-site laboratories. Phenotypic testing of drug susceptibility to at least isoniazid, rifampin, and fluoroquinolones was performed on the <i>M. tuberculosis</i> isolates obtained at baseline and on the first of any <i>M. tuberculosis</i> isolates obtained at or after week 17. Whole-genome sequencing was used to compare the <i>M. tuberculosis</i> isolate obtained from a participant at baseline with any isolate obtained at or after week 17.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup> The microbiologists who handled the sputum specimens and the clinical trial operations team at the Data and Coordinating Center were unaware of the treatment-group assignments and trial week.</div></section><section id="sec-1-5"><h3>Trial Outcomes</h3><div role="paragraph">The primary efficacy outcome was survival free of tuberculosis at 12 months after randomization (see the <a href="#ap2">Supplementary Appendix</a>).<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> The total duration of follow-up was 18 months. A secondary efficacy outcome analysis that considers survival free of tuberculosis at 18 months has not yet been performed. The status with respect to the primary outcome (favorable, unfavorable, or not assessable) was determined for each participant. Favorable status was assigned if a participant met all the following criteria: was alive and free of tuberculosis at 12 months after randomization; did not meet the criteria for unfavorable or not-assessable status; and had either an <i>M. tuberculosis</i>–negative result on the sputum culture at month 12 or, at month 12, was unable to produce sputum or produced sputum that was contaminated but without evidence of <i>M. tuberculosis</i>. Unfavorable status was assigned if a participant had <i>M. tuberculosis</i>–positive cultures from two sputum specimens obtained at or after week 17 without an intervening negative culture, died or was withdrawn from the trial or lost to follow-up during the treatment period, had an <i>M. tuberculosis</i>–positive culture when last seen, died from tuberculosis during the post-treatment follow-up, or received additional treatment for tuberculosis. Status was not assessable if a participant did not already have an unfavorable outcome and met any one of the following criteria: did not attend the month 12 visit but had a negative culture when last seen, had a change in treatment because of pregnancy, died from a cause unrelated to tuberculosis during the follow-up period, received additional treatment for tuberculosis after exogenous reinfection was identified on whole-genome sequencing, or died from a violent cause or had an accidental death during the treatment period. Stable conversion of sputum cultures to negative was defined as two negative cultures without an intervening positive culture.</div><div role="paragraph">The primary safety outcome was an adverse event of grade 3 or higher with an onset during the on-treatment period (defined as the period during which the trial medications were administered and up to 14 days after the last dose). Adverse events were graded by the site investigators according to National Cancer Institute Common Terminology Criteria for Adverse Events.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31-1" href-manipulated="true" aria-label="Reference 31">31</a></sup> Premature discontinuation was recorded when an assigned regimen was discontinued prematurely for a reason other than microbiologic ineligibility. The trial was reviewed annually by a data and safety monitoring board.</div></section><section id="sec-1-6"><h3>Analysis Populations</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The primary analysis was performed in the microbiologically eligible and the assessable analysis populations.</span> The microbiologically eligible population included all the participants except those who had no evidence of <i>M. tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria; the participants with an outcome status that was not assessable were reclassified as having had an unfavorable outcome. The assessable population included the participants in the microbiologically eligible population who met the criteria for favorable or unfavorable status with respect to the primary outcome. Secondary analysis populations included the per-protocol 95% and per-protocol 75% populations, in which participants who did not complete 95% or 75% of treatment doses, respectively, were excluded unless the reason for inadequate treatment was death or bacteriologic treatment failure, and the intention-to-treat analysis population, which included all participants who had undergone randomization. A total of 15 sensitivity analyses were prespecified in the statistical analysis plan, available with the <a href="#ap1">protocol</a>.</div></section><section id="sec-1-7"><h3>Statistical Analysis</h3><div role="paragraph">Assuming that 15% of the participants who could be assessed would have an unfavorable outcome, that an additional 12% would be excluded from the microbiologically eligible population, and that a further 12% would have an outcome status that could not be assessed, we estimated that a sample size of 2500 participants would provide the trial with 90% power (in the assessable population) and 80% power (in the microbiologically eligible population) to test the primary hypotheses that the 4-month rifapentine–moxifloxacin regimen or the 4-month rifapentine regimen would be noninferior to the 6-month standard control regimen, with a noninferiority margin of 6.6 percentage points and a two-sided type I error rate of 5%.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r32 r33" id="body-ref-r33" href-manipulated="true">16,32,33</a></sup> In the primary efficacy analysis, we calculated the absolute between-group difference, with the 95% confidence interval, in the percentage of participants who had a favorable outcome, with adjustment for cavitation on chest radiography and HIV status using Cochran–Mantel–Haenszel weights.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> Noninferiority was shown if the upper boundary of the 95% confidence interval around the difference was 6.6 percentage points or less in both the microbiologically eligible and the assessable analysis populations. To account for multiplicity, a hierarchical ordering of hypotheses was prespecified in the protocol — the rifapentine–moxifloxacin group was compared with the control group first, and if noninferiority was demonstrated, the rifapentine group was compared with the control group.</div><div role="paragraph">A noninferiority margin of 6.6 percentage points was calculated to preserve more than 50% of the treatment effect of the control regimen and was considered to be an acceptable difference in efficacy, given the shorter treatment duration (see the <a href="#ap2">Supplementary Appendix</a>). The safety analysis population included all the participants who had undergone randomization and received at least one dose of the assigned treatment; the analysis of premature discontinuation of the assigned regimen was performed in the microbiologically eligible population. In the safety analyses, we calculated the absolute between-group differences, with 95% confidence intervals, with adjustment for baseline randomization factors. The time to an unfavorable outcome was calculated as the time from randomization to the event that caused the unfavorable outcome. For the time-to-event analyses, Cox regression was used to calculate a hazard ratio and 95% confidence interval stratified according to the randomization factors of HIV status and cavitation on chest radiography, and Schoenfeld residuals were used to test the proportional-hazards assumption. Apart from the primary efficacy analyses, between-group differences and confidence intervals were not adjusted for multiplicity and therefore cannot be used to infer treatment effects.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Population</h3><div role="paragraph"><a id="exam-tint-three-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="three-d">Between January 25, 2016, and October 30, 2018, a total of 5124 patients underwent screening at 34 trial sites in Brazil, China (Hong Kong), Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, the United States, Vietnam, and Zimbabwe, and 2516 were randomly assigned to a treatment group.</span> A total of 173 participants who had undergone randomization were excluded from the microbiologically eligible population, which comprised 2343 participants (768 were in the control group, 791 in the rifapentine–moxifloxacin group, and 784 in the rifapentine group) (<a href="#f1">Figure 1</a>). The assessable population comprised 2234 participants (726 were in the control group, 756 in the rifapentine–moxifloxacin group, and 752 in the rifapentine group). The baseline demographic and clinical characteristics of the participants were similar in the three treatment groups (<a href="#t1">Table 1</a>). Among the participants in the microbiologically eligible population, 728 (94.8%) in the control group, 759 (96.0%) in the rifapentine–moxifloxacin group, and 754 (96.2%) in the rifapentine group were retained in the trial through the end of the 12-month follow-up or were known to have died during this period.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f1.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/6d56e303-6e87-4c44-9ea8-1166a19e1618/assets/images/large/nejmoa2033400_f1.jpg" height="2935" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">MTB denotes <i>Mycobacterium tuberculosis</i>.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/45f30825-764c-42a4-a52e-5e69d75cc419/assets/images/large/nejmoa2033400_t1.jpg" height="2245" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Control<br>(N=768)</th><th class="txxx-borders">Rifapentine–Moxifloxacin<br>(N=791)</th><th class="txxx-borders">Rifapentine<br>(N=784)</th><th class="txxr-borders">Total<br>(N=2343)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Male sex — no./total no. (%)</td><td class="xxxx-borders shading">544/768 (71)</td><td class="xxxx-borders shading">563/791 (71)</td><td class="xxxx-borders shading">563/784 (72)</td><td class="xxxr-borders shading">1670/2343 (71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders">30.9 (13.7–77.5)</td><td class="xxxx-borders">31.0 (14.6–72.5)</td><td class="xxxx-borders">31.0 (14.1–81.4)</td><td class="xxxr-borders">31.0 (13.7–81.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age group — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">12–17 yr</td><td class="xxxx-borders">19/768 (2)</td><td class="xxxx-borders">25/791 (3)</td><td class="xxxx-borders">19/784 (2)</td><td class="xxxr-borders">63/2343 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18–35 yr</td><td class="xxxx-borders shading">479/768 (62)</td><td class="xxxx-borders shading">486/791 (61)</td><td class="xxxx-borders shading">485/784 (62)</td><td class="xxxr-borders shading">1450/2343 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&gt;35 yr</td><td class="xxxx-borders">270/768 (35)</td><td class="xxxx-borders">280/791 (35)</td><td class="xxxx-borders">280/784 (36)</td><td class="xxxr-borders">830/2343 (35)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no./total no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">86/765 (11)</td><td class="xxxx-borders">89/790 (11)</td><td class="xxxx-borders">93/783 (12)</td><td class="xxxr-borders">268/2338 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">553/765 (72)</td><td class="xxxx-borders shading">552/790 (70)</td><td class="xxxx-borders shading">571/783 (73)</td><td class="xxxr-borders shading">1676/2338 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">15/765 (2)</td><td class="xxxx-borders">13/790 (2)</td><td class="xxxx-borders">8/783 (1)</td><td class="xxxr-borders">36/2338 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Multiracial</td><td class="xxxx-borders shading">111/765 (15)</td><td class="xxxx-borders shading">136/790 (17)</td><td class="xxxx-borders shading">111/783 (14)</td><td class="xxxr-borders shading">358/2338 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">HIV positivity — no./total no. (%)</td><td class="xxxx-borders">64/768 (8)</td><td class="xxxx-borders">62/791 (8)</td><td class="xxxx-borders">68/784 (9)</td><td class="xxxr-borders">194/2343 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median CD4 count among those with HIV positivity (IQR)</td><td class="xxxx-borders shading">334 (249–485)</td><td class="xxxx-borders shading">346 (253–458)</td><td class="xxxx-borders shading">351 (221–437)</td><td class="xxxr-borders shading">344 (223–455)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cavitation on chest radiography — no./total no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">206/768 (27)</td><td class="xxxx-borders shading">213/791 (27)</td><td class="xxxx-borders shading">206/784 (26)</td><td class="xxxr-borders shading">625/2343 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;4 cm</td><td class="xxxx-borders">251/768 (33)</td><td class="xxxx-borders">277/791 (35)</td><td class="xxxx-borders">246/784 (31)</td><td class="xxxr-borders">774/2343 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥4 cm</td><td class="xxxx-borders shading">307/768 (40)</td><td class="xxxx-borders shading">295/791 (37)</td><td class="xxxx-borders shading">327/784 (42)</td><td class="xxxr-borders shading">929/2343 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body weight — kg</td><td class="xxxx-borders">52.0</td><td class="xxxx-borders">53.0</td><td class="xxxx-borders">53.3</td><td class="xxxr-borders">53.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO smear grade — no./total no. (%)<a href="#t1fn4" role="doc-noteref">§</a><a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">21/766 (2.7)</td><td class="xxxx-borders">31/789 (3.9)</td><td class="xxxx-borders">36/782 (4.6)</td><td class="xxxr-borders">88/2337 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Scanty or 1–9 acid-fast bacilli</td><td class="xxxx-borders shading">121/766 (15.8)</td><td class="xxxx-borders shading">147/789 (18.6)</td><td class="xxxx-borders shading">124/782 (15.9)</td><td class="xxxr-borders shading">392/2337 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1+</td><td class="xxxx-borders">187/766 (24.4)</td><td class="xxxx-borders">168/789 (21.3)</td><td class="xxxx-borders">172/782 (22.0)</td><td class="xxxr-borders">527/2337 (22.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2+</td><td class="xxxx-borders shading">229/766 (29.9)</td><td class="xxxx-borders shading">228/789 (28.9)</td><td class="xxxx-borders shading">227/782 (29.0)</td><td class="xxxr-borders shading">684/2337 (29.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3+</td><td class="xxxx-borders">198/766 (25.8)</td><td class="xxxx-borders">209/789 (26.5)</td><td class="xxxx-borders">214/782 (27.4)</td><td class="xxxr-borders">621/2337 (26.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Positive smear, WHO scale not used<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">10/766 (1.3)</td><td class="xxxx-borders shading">6/789 (0.8)</td><td class="xxxx-borders shading">9/782 (1.2)</td><td class="xxxr-borders shading">25/2337 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (range)<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">18.9 (12.8–45.2)</td><td class="xxxx-borders">19.0 (14.1–39.1)</td><td class="xxxx-borders">18.9 (13.4–35.4)</td><td class="xxxr-borders">18.9 (12.8–45.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Current smoker — no./total no. (%)</td><td class="xxxx-borders shading">196/768 (26)</td><td class="xxxx-borders shading">175/791 (22)</td><td class="xxxx-borders shading">200/784 (26)</td><td class="xxxr-borders shading">571/2343 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Prior course of tuberculosis treatment — no./total no. (%)</td><td class="xbxx-borders">83/768 (11)</td><td class="xbxx-borders">97/791 (12)</td><td class="xbxx-borders">85/784 (11)</td><td class="xbxr-borders">265/2343 (11)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Participants at Baseline in the Microbiologically Eligible Population.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The microbiologically eligible population included all the participants except those who had no evidence of <i>Mycobacterium tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria. HIV denotes human immunodeficiency virus, and IQR interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the trial participants; information about race was not available for 5 participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Cavity size refers to the aggregate diameter of all cavities.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Sputum smears were not available for 6 participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Sputum smears were graded according to the World Health Organization (WHO) classification, which provides different criteria for each grade depending on the type of microscopy and magnification used at the site laboratory.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35" href-manipulated="true" aria-label="Reference 35">35</a></sup></div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary Outcome</h3><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">In the comparison between the rifapentine–moxifloxacin group and the control group, noninferiority was confirmed in both analysis populations. In the microbiologically eligible population, an unfavorable outcome occurred in 15.5% of the participants in the rifapentine–moxifloxacin group and in 14.6% of those in the control group, for an adjusted absolute difference of 1.0 percentage points (95% confidence interval [CI], −2.6 to 4.5). The corresponding values in the assessable population were 11.6% and 9.6%, for an adjusted absolute difference of 2.0 percentage points (95% CI, −1.1 to 5.1) (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2A</a>). The rifapentine regimen was not shown to be noninferior to the control regimen in either analysis population (adjusted absolute differences of 3.0 percentage points [95% CI, −0.6 to 6.6] in the microbiologically eligible population and 4.4 percentage points [95% CI, 1.2 to 7.7] in the assessable population).</span> The time from randomization to an unfavorable outcome among the participants in the assessable population is shown in <a href="#f2">Figure 2B</a>, with censoring of the data from the participants who could not be assessed. The results in the per-protocol and intention-to-treat populations and the results of further sensitivity analyses of the primary efficacy outcome were consistent with the findings in the microbiologically eligible and the assessable analysis populations (<a href="#f2">Figure 2A</a>, Tables S3 and S4, and Figs. S2 and S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f2.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/f32abf9b-efd9-42ad-ba9a-f6785d479fd2/assets/images/large/nejmoa2033400_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Primary and Secondary Efficacy Analyses and Time to an Unfavorable Outcome.</div><div class="notes"><div role="doc-footnote">Panel A shows the results of the primary efficacy analysis in the microbiologically eligible and the assessable analysis populations and of the secondary analyses in the intention-to-treat and the per-protocol analysis populations (top, rifapentine–moxifloxacin regimen vs. control regimen; bottom, rifapentine regimen vs. control regimen). The noninferiority margin of 6.6 percentage points is designated by the dashed vertical line. Participants were classified as having an unfavorable outcome if they had <i>M. tuberculosis</i>–positive cultures from two sputum specimens obtained at or after week 17 without an intervening negative culture, died or were withdrawn from the trial or lost to follow-up during the treatment period, had an <i>M. tuberculosis</i>–positive culture when last seen, died from tuberculosis during the post-treatment follow-up, or received additional treatment for tuberculosis. The microbiologically eligible analysis population included all the participants except those who had no evidence of <i>M. tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria; the participants with an outcome status that was not assessable were reclassified as having had an unfavorable outcome. The assessable analysis population included the participants in the microbiologically eligible population except those whose outcome status had been reclassified from not assessable to unfavorable. The per-protocol 75% and per-protocol 95% analysis populations included the participants in the assessable population, except those who did not complete 75% or 95% of the assigned treatment doses, respectively, unless the reason for inadequate treatment was death or bacteriologic treatment failure. Panel B shows the results for the time to unfavorable outcome for the microbiologically eligible population. Data were censored for the participants who could not be assessed. HIV denotes human immunodeficiency virus. The inset shows the same data on an expanded y axis.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t2.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/b075d434-2885-4b8f-bd38-88d9fa13055b/assets/images/large/nejmoa2033400_t2.jpg" height="2334" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Microbiologically Eligible Population</span></th><th class="txxr-borders" colspan="4"><span>Assessable Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Control<br>(N=768)</th><th class="xxxx-borders">Rifapentine–Moxifloxacin<br>(N=791)</th><th class="xxxx-borders">Rifapentine<br>(N=784)</th><th class="xxxx-borders">Total<br>(N=2343)</th><th class="xxxx-borders">Control<br>(N=726)</th><th class="xxxx-borders">Rifapentine–Moxifloxacin<br>(N=756)</th><th class="xxxx-borders">Rifapentine<br>(N=752)</th><th class="xxxr-borders">Total<br>(N=2234)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Favorable</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders">656 (85.4)</td><td class="xxxx-borders">668 (84.5)</td><td class="xxxx-borders">645 (82.3)</td><td class="xxxx-borders">1969 (84.0)</td><td class="xxxx-borders">656 (90.4)</td><td class="xxxx-borders">668 (88.4)</td><td class="xxxx-borders">645 (85.8)</td><td class="xxxr-borders">1969 (88.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted difference from control — percentage points (95% CI)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">1.0 (−2.6 to 4.5)</td><td class="xxxx-borders shading">3.0 (−0.6 to 6.6)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">2.0 (−1.1 to 5.1)</td><td class="xxxx-borders shading">4.4 (1.2 to 7.7)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participant had negative culture at month 12 — no. (%)</td><td class="xxxx-borders">643 (83.7)</td><td class="xxxx-borders">656 (82.9)</td><td class="xxxx-borders">636 (81.1)</td><td class="xxxx-borders">1935 (82.6)</td><td class="xxxx-borders">643 (88.6)</td><td class="xxxx-borders">656 (86.8)</td><td class="xxxx-borders">636 (84.6)</td><td class="xxxr-borders">1935 (86.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participant was seen at month 12 but no sputum was produced or cultures were contaminated but without evidence of <i>M. tuberculosis</i> — no. (%)</td><td class="xxxx-borders shading">13 (1.7)</td><td class="xxxx-borders shading">12 (1.5)</td><td class="xxxx-borders shading">9 (1.1)</td><td class="xxxx-borders shading">34 (1.5)</td><td class="xxxx-borders shading">13 (1.8)</td><td class="xxxx-borders shading">12 (1.6)</td><td class="xxxx-borders shading">9 (1.2)</td><td class="xxxr-borders shading">34 (1.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Unfavorable</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders shading">112 (14.6)</td><td class="xxxx-borders shading">123 (15.5)</td><td class="xxxx-borders shading">139 (17.7)</td><td class="xxxx-borders shading">374 (16.0)</td><td class="xxxx-borders shading">70 (9.6)</td><td class="xxxx-borders shading">88 (11.6)</td><td class="xxxx-borders shading">107 (14.2)</td><td class="xxxr-borders shading">265 (11.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Outcome related to tuberculosis — no. (%)</td><td class="xxxx-borders">24 (3.1)</td><td class="xxxx-borders">45 (5.7)</td><td class="xxxx-borders">75 (9.6)</td><td class="xxxx-borders">144 (6.1)</td><td class="xxxx-borders">24 (3.3)</td><td class="xxxx-borders">45 (6.0)</td><td class="xxxx-borders">75 (10.0)</td><td class="xxxr-borders">144 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Two consecutive positive cultures at or after week 17<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">11 (1.4)</td><td class="xxxx-borders shading">34 (4.3)</td><td class="xxxx-borders shading">63 (8.0)</td><td class="xxxx-borders shading">108 (4.6)</td><td class="xxxx-borders shading">11 (1.5)</td><td class="xxxx-borders shading">34 (4.5)</td><td class="xxxx-borders shading">63 (8.4)</td><td class="xxxr-borders shading">108 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Participant not seen at month 12 but had positive culture when last seen</td><td class="xxxx-borders">11 (1.4)</td><td class="xxxx-borders">3 (0.4)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">18 (0.8)</td><td class="xxxx-borders">11 (1.5)</td><td class="xxxx-borders">3 (0.4)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxr-borders">18 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Clinical diagnosis of tuberculosis recurrence and treatment restarted</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">18 (0.8)</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">8 (1.1)</td><td class="xxxx-borders shading">8 (1.1)</td><td class="xxxr-borders shading">18 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Outcome not related to tuberculosis — no. (%)</td><td class="xxxx-borders">46 (6.0)</td><td class="xxxx-borders">43 (5.4)</td><td class="xxxx-borders">32 (4.1)</td><td class="xxxx-borders">121 (5.2)</td><td class="xxxx-borders">46 (6.3)</td><td class="xxxx-borders">43 (5.7)</td><td class="xxxx-borders">32 (4.3)</td><td class="xxxr-borders">121 (5.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Consent withdrawn during treatment period with no adverse event reported</td><td class="xxxx-borders shading">14 (1.8)</td><td class="xxxx-borders shading">15 (1.9)</td><td class="xxxx-borders shading">11 (1.4)</td><td class="xxxx-borders shading">40 (1.7)</td><td class="xxxx-borders shading">14 (1.9)</td><td class="xxxx-borders shading">15 (2.0)</td><td class="xxxx-borders shading">11 (1.5)</td><td class="xxxr-borders shading">40 (1.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change in treatment because of adverse event</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">16 (2.0)</td><td class="xxxx-borders">9 (1.1)</td><td class="xxxx-borders">33 (1.4)</td><td class="xxxx-borders">8 (1.1)</td><td class="xxxx-borders">16 (2.1)</td><td class="xxxx-borders">9 (1.2)</td><td class="xxxr-borders">33 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death during treatment period</td><td class="xxxx-borders shading">7 (0.9)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">13 (0.6)</td><td class="xxxx-borders shading">7 (1.0)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxr-borders shading">13 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Loss to follow-up during treatment period</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">12 (0.5)</td><td class="xxxx-borders">8 (1.1)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxr-borders">12 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Consent withdrawn during treatment period after occurrence of adverse event</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">8 (0.3)</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxr-borders shading">8 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treatment changed or restarted for other reasons</td><td class="xxxx-borders">7 (0.9)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">15 (0.6)</td><td class="xxxx-borders">7 (1.0)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxr-borders">15 (0.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Not assessable</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders">42 (5.5)</td><td class="xxxx-borders">32 (4.0)</td><td class="xxxx-borders">35 (4.5)</td><td class="xxxx-borders">109 (4.7)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Participant not seen at month 12 but had negative culture when last seen</td><td class="xxxx-borders shading">31 (4.0)</td><td class="xxxx-borders shading">22 (2.8)</td><td class="xxxx-borders shading">23 (2.9)</td><td class="xxxx-borders shading">76 (3.2)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treatment discontinued because of pregnancy</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">5 (0.6)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">17 (0.7)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death unrelated to tuberculosis during follow-up</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">14 (0.6)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Violent or accidental death during treatment period</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.1)</td><td class="xxxx-borders">1 (&lt;0.1)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Exogenous reinfection confirmed on WGS</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">1 (0.1)</td><td class="xbxx-borders shading">1 (&lt;0.1)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">NA</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="caption">Primary Efficacy Analysis in the Microbiologically Eligible and the Assessable Populations.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The assessable population included the participants in the microbiologically eligible population who met the criteria for favorable or unfavorable status with respect to the primary outcome. NA denotes not applicable, and WGS whole-genome sequencing.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Among the participants who had a microbiologically unfavorable outcome, one in the rifapentine–moxifloxacin group had an isolate of recurrent <i>Mycobacterium tuberculosis</i> that showed phenotypic evidence of resistance to isoniazid plus rifampin but was susceptible to isoniazid and rifampin on line-probe molecular testing (WGS results were not available) and three in the rifapentine group had isolates of recurrent <i>M. tuberculosis</i> that showed evidence of resistance to isoniazid plus rifampin (WGS results were not available).</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Subgroup Analyses</h3><div role="paragraph">No evidence was found of a difference in efficacy between the rifapentine–moxifloxacin group and the control group in any of the prespecified subgroup analyses (Fig. S4). In contrast, the difference in efficacy observed between the rifapentine group and the control group was smaller in certain subgroups, including female participants, participants without cavitation, participants with low-grade smear, and participants with a long time to positivity for <i>M. tuberculosis</i> growth in baseline liquid cultures (Fig. S5).</div></section><section id="sec-2-4"><h3>Time to Culture Conversion</h3><div role="paragraph">The time to stable conversion of sputum cultures to negative was shorter in the 4-month regimen groups than that in the control group — the hazard ratios for stable culture conversion in the rifapentine–moxifloxacin group as compared with the control group were 1.4 (95% CI, 1.2 to 1.5) in liquid media and 1.3 (95% CI, 1.2 to 1.5) on solid media, and the hazard ratios in the rifapentine group as compared with the control group were 1.3 (95% CI, 1.2 to 1.4) in liquid media and 1.3 (95% CI, 1.2 to 1.4) on solid media (Tables S5 and S6 and Figs. S6 and S7). Among the participants in the microbiologically eligible population, culture conversion in liquid media occurred by 8 weeks (up to 70 days) in 63.4% of those in the control group, 78.5% of those in the rifapentine–moxifloxacin group, and 74.2% of those in the rifapentine group.</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph">No evidence was found of a difference in the percentage of participants who had an adverse event of grade 3 or higher (the primary safety outcome) during the on-treatment period between the rifapentine–moxifloxacin group and the control group (18.8% [159 participants] vs. 19.3% [159]; adjusted difference, −0.6 percentage points; 95% CI, −4.3 to 3.2) (<a href="#t3">Table 3</a> and Table S7). The percentage of participants who had an adverse event of grade 3 or higher during the on-treatment period was lower in the rifapentine group (14.3% [119 participants]) than in the control group (adjusted difference, −5.1 percentage points; 95% CI, −8.7 to −1.5). All-cause mortality during the on-treatment period was similar across the treatment regimens (7 participants [0.8%] in the control group, 3 [0.4%] in the rifapentine–moxifloxacin group, and 4 [0.5%] in the rifapentine group) (<a href="#t3">Table 3</a>, Tables S8 through S10, and Fig. S8).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/1c7f2a82-c984-4a8d-8a61-751da439eb3e/assets/images/large/nejmoa2033400_t3.jpg" height="2157" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Control<br>(N=825)</th><th class="txxx-borders">Rifapentine–Moxifloxacin<br>(N=846)</th><th class="txxx-borders">Rifapentine<br>(N=835)</th><th class="txxr-borders">Total<br>(N=2506)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary safety outcome</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Grade 3 or higher adverse event — no. (%)</td><td class="xxxx-borders">159 (19.3)</td><td class="xxxx-borders">159 (18.8)</td><td class="xxxx-borders">119 (14.3)</td><td class="xxxr-borders">437 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">−0.6 (−4.3 to 3.2)</td><td class="xxxx-borders shading">−5.1 (−8.7 to −1.5)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Secondary safety outcome</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Treatment-related grade 3 or higher adverse event — no. (%)</td><td class="xxxx-borders shading">81 (9.8)</td><td class="xxxx-borders shading">109 (12.9)</td><td class="xxxx-borders shading">64 (7.7)</td><td class="xxxr-borders shading">254 (10.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">NA</td><td class="xxxx-borders">3.0 (−0.0 to 6.1)</td><td class="xxxx-borders">−2.2 (−4.9 to 0.6)</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Other safety outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any serious adverse event — no. (%)</td><td class="xxxx-borders">56 (6.8)</td><td class="xxxx-borders">37 (4.4)</td><td class="xxxx-borders">39 (4.7)</td><td class="xxxr-borders">132 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death — no. (%)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">7 (0.8)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">4 (0.5)</td><td class="xxxr-borders shading">14 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any adverse event resulting in discontinuation of assigned treatment — no. (%)<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7 (0.8)</td><td class="xxxx-borders">16 (1.9)</td><td class="xxxx-borders">11 (1.3)</td><td class="xxxr-borders">34 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any grade 3 or higher adverse event within 28 weeks after randomization</td><td class="xxxx-borders shading">159 (19.3)</td><td class="xxxx-borders shading">194 (22.9)</td><td class="xxxx-borders shading">138 (16.5)</td><td class="xxxr-borders shading">491 (19.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">ALT or AST level ≥5×ULN — no. (%)<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">24 (2.9)</td><td class="xxxx-borders">16 (1.9)</td><td class="xxxx-borders">13 (1.6)</td><td class="xxxr-borders">53 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">ALT or AST level ≥10×ULN — no. (%)</td><td class="xxxx-borders shading">9 (1.1)</td><td class="xxxx-borders shading">4 (0.5)</td><td class="xxxx-borders shading">5 (0.6)</td><td class="xxxr-borders shading">18 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Serum total bilirubin level ≥3×ULN — no. (%)<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">28 (3.3)</td><td class="xxxx-borders">20 (2.4)</td><td class="xxxr-borders">56 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hy’s law criteria of ALT or AST level ≥3×ULN plus serum total bilirubin level ≥2×ULN — no. (%)</td><td class="xxxx-borders shading">7 (0.8)</td><td class="xxxx-borders shading">10 (1.2)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxr-borders shading">25 (1.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Premature discontinuation of assigned regimen in the microbiologically eligible population</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Discontinuation of assigned regimen for any reason — no./total no. (%)</td><td class="xxxx-borders shading">61/768 (7.9)</td><td class="xxxx-borders shading">55/791 (7.0)</td><td class="xxxx-borders shading">37/784 (4.7)</td><td class="xxxr-borders shading">153/2343 (6.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#t3fn3" role="doc-noteref">†</a></td><td class="xbxx-borders">NA</td><td class="xbxx-borders">−1.0 (−3.6 to 1.6)</td><td class="xbxx-borders">−3.3 (−5.7 to −0.9)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="caption">Safety and Premature Discontinuation of Assigned Regimen.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The safety analysis population included all the participants who had undergone randomization and received at least one dose of the assigned treatment. Safety was assessed during the on-treatment period (the time during which the participants were receiving the trial medications and up to 14 days after the last dose), unless otherwise specified. Adverse events were graded by the site investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31-2" href-manipulated="true" aria-label="Reference 31">31</a></sup> ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and ULN upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The analysis was adjusted for the stratification factors of presence of cavitation on baseline chest radiography at baseline and HIV status.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">In the control group, death was due to paracoccidioides infection, sepsis, papillary thyroid cancer, central nervous system lesion, hemoptysis, or pulmonary embolism (in 1 participant each), and there was one unexplained death. In the rifapentine–moxifloxacin group, death was due to thrombotic thrombocytopenic purpura, congestive cardiac failure, or pulmonary tuberculosis (in 1 participant each). In the rifapentine group, death was due to alcohol poisoning, road traffic accident, or pulmonary embolism (in 1 participant each), and there was one unexplained death.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The assigned treatment was discontinued because of hepatitis (in 6 participants) or seizure (in 1 participant) in the control group; because of hepatitis (in 11 participants) or thrombocytopenia, QT prolongation, tendonitis, pruritus, or maculopapular rash (in 1 participant each) in the rifapentine–moxifloxacin group; and because of hepatitis (in 8 participants) or neutropenia, bacterial pneumonia, or drug reaction with eosinophilia and systemic symptoms (in 1 participant each) in the rifapentine group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">An ALT or AST level of at least 5×ULN corresponds with an adverse event of grade 3 or higher.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">A total bilirubin level of at least 3×ULN corresponds with an adverse event of grade 3 or higher.</div></div></div></figcaption></figure></div><div role="paragraph">With regard to adverse events of interest (i.e., those known to be associated with a medication), the percentages of participants with grade 3 or higher alanine aminotransferase or aspartate aminotransferase levels were similar across the treatment regimens. <a id="exam-tint-two-a"></a><a id="exam-tint-two-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-d">A grade 3 or higher serum total bilirubin level was reported in a higher percentage of participants in the rifapentine-based regimen groups than in the control group (1.0% [8 participants] in the control group, 3.3% [28] in the rifapentine–moxifloxacin group, and 2.4% [20] in the rifapentine group), although 25 adverse events that met the Hy’s law criteria for drug-induced liver injury were distributed equally across the treatment groups (<a href="#t3">Table 3</a> and Fig. S9).<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36-1" href-manipulated="true" aria-label="Reference 36">36</a></sup> Cardiac disorders of grade 3 or higher that occurred during the on-treatment period were reported in 3 participants (0.4%) in the rifapentine–moxifloxacin group — two events were considered by the site investigators as unlikely to be related to the trial regimen, and one event, reported as palpitations with borderline electrocardiographic QT prolongation, was considered to be related to the trial regimen (Table S11). No evidence was found of a difference in premature discontinuation between the rifapentine–moxifloxacin group and the control group (risk difference, −1.0 percentage points; 95% CI, −3.6 to 1.6). Premature discontinuation occurred less frequently with the rifapentine regimen than with the control regimen (−3.3 percentage points; 95% CI, −5.7 to −0.9).</span></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this phase 3 trial, the efficacy of the 4-month regimen containing rifapentine and moxifloxacin was noninferior to that of the standard 6-month regimen. Noninferiority of the rifapentine–moxifloxacin regimen to the control regimen was confirmed across analysis populations as well as in sensitivity and prespecified subgroup analyses. The efficacy of the 4-month regimen containing rifapentine without moxifloxacin did not meet the criteria for noninferiority.</div><div role="paragraph"><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-b two-c">The incidence of grade 3 or higher adverse events during the on-treatment period was similar in the rifapentine–moxifloxacin group and the control group and was slightly lower in the rifapentine group.</span> We observed a higher incidence of hyperbilirubinemia in the rifapentine-based regimen groups, but there was no notable difference among the three treatment groups in the percentage of participants who had elevations in serum aminotransferase levels or who met the criteria of Hy’s law.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36-2" href-manipulated="true" aria-label="Reference 36">36</a></sup> Rifamycins can increase the serum bilirubin level through dose-dependent interference with bilirubin uptake that is typically subclinical and not associated with hepatocellular injury.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37 r38" id="body-ref-r38" href-manipulated="true">37,38</a></sup> Nevertheless, careful monitoring for hepatotoxicity should be performed during the course of the 4-month rifapentine-based regimens, given the theoretical increase in the risk of hepatotoxicity with increased exposure to a rifamycin, the difficulty of detecting signals of rare events in clinical trials, and the known risk of severe hepatitis associated with tuberculosis treatment regimens containing rifamycins, isoniazid, or pyrazinamide. There was no clinical evidence of increased risk of cardiotoxicity, although electrocardiographic monitoring was not a required component of the study.<sup><a href="#core-r39" role="doc-biblioref" data-xml-rid="r39" id="body-ref-r39" href-manipulated="true" aria-label="Reference 39">39</a></sup></div><div role="paragraph">Antimicrobial activity, as assessed with the use of the intermediate marker of time to stable conversion of sputum cultures to negative, was greater with the experimental 4-month regimens than with the control regimen, a finding that was consistent with the result in a phase 2 trial.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-4" href-manipulated="true" aria-label="Reference 22">22</a></sup> However, this marker differed little between the two rifapentine-based regimens, despite the difference in their ability to cure tuberculosis. This finding highlights the limitations of the use of sputum-culture conversion as a surrogate marker for cure and underscores both the importance of trials that use clinically relevant outcomes and the need for better markers of early response to treatment.</div><div role="paragraph">Our trial has several limitations. Placebos were not used, and therefore neither the participants nor the staff at the trial site were unaware of the treatment-group assignment. The rationale for this approach was twofold. First, food affects rifampin and rifapentine differently; therefore, the provision of treatment-specific guidance on whether to take a medication with or without food was needed to increase exposure to the rifamycin used in each trial regimen.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r27" id="body-ref-r27-2" href-manipulated="true">8,27</a></sup> Second, the use of placebos would have increased the number of daily pills to approximately 20, potentially affecting the rate of premature discontinuation. We minimized measurement bias by concealing both the treatment-group assignments and the trial week from the microbiologists handling sputum specimens and the team at the data coordinating center. The trial incorporated uniform visits and procedures regardless of treatment assignment and included a prespecified set of triggers and processes for evaluating participants who might not be responding well to treatment.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-4" href-manipulated="true" aria-label="Reference 23">23</a></sup> Only the members of the data and safety monitoring board and the statisticians reporting to the data and safety monitoring board saw the aggregate data according to treatment group before the end of the trial. <a id="exam-tint-three-a"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a">A total of 8% of the trial participants were coninfected with HIV, a fact that limits the power to compare regimens in this trial population.</span></div><div role="paragraph"><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-b three-c three-d">Strengths of the trial include a high rate of retention of participants and the completeness of data from mycobacteriologic testing, both of which reflect the quality of trial implementation. In this noninferiority trial involving ambulatory participants, the validity of the results is supported by the finding that 96.9% of the participants who were assigned to the control regimen in the per-protocol 75% analysis population (a secondary analysis that was chosen to be comparable with the per-protocol analyses in recent trials) had a favorable outcome rate. This finding reflects the reported cure rates with the same regimen in trials conducted in the late 20th century, which involved mostly hospitalized patients.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r32 r40" id="body-ref-r40" href-manipulated="true">16,32,40</a></sup> Other strengths are the inclusion of adolescents and adults from diverse populations in regions with varied burden of tuberculosis on four continents and the performance of microbiologic assays under rigorous quality management.</span></div><div role="paragraph">In considering the feasibility of using the rifapentine–moxifloxacin regimen in national tuberculosis programs, several issues are relevant. First, rapid drug-susceptibility testing to fluoroquinolones and isoniazid should be performed in addition to the widely available rapid molecular drug susceptibility testing for rifampin. This should be surmountable, because the genetic basis of <i>M. tuberculosis</i> resistance to isoniazid and fluoroquinolones is established, and rapid molecular tests are in advanced stages of clinical testing.<sup><a href="#core-r41" role="doc-biblioref" data-xml-rid="r41 r42" id="body-ref-r42" href-manipulated="true">41,42</a></sup> Second, absorption of rifapentine in the gut is improved in the presence of high-fat foods.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-3" href-manipulated="true" aria-label="Reference 27">27</a></sup> In our trial, the determination of the dose of rifapentine and the guidance to take the medication with any food were based on evidence and were pragmatically selected to achieve desirable pharmacokinetic exposures in a manner likely to be feasible in most settings.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r22" id="body-ref-r22-5" href-manipulated="true">7,22</a></sup> The trial incorporated a pharmacokinetic component that will allow a nuanced understanding of drug exposure–response relationships across populations. Finally, drug costs may be higher for the rifapentine–moxifloxacin regimen than for the current standard 6-month regimen, at least in the short term. Economic analyses will provide information about the extent to which incrementally higher drug costs are offset by a shorter regimen.</div><div role="paragraph">In this trial, a 4-month regimen that included rifapentine at a daily dose of 1200 mg and moxifloxacin at daily dose of 400 mg had an efficacy that was noninferior to that of the standard 6-month regimen across the primary, secondary, and sensitivity analysis populations.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC), the National Institute of Allergy and Infectious Diseases, or the Department of Health and Human Services.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by the <span class="named-content" data-type="funder">CDC</span>; the Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (contracts 200-2009-32582, 200-2009-32593, 200-2009-32594, 200-2009-32589, 200-2009-32597, 200-2009-32598, 75D30119C06702, 75D30119C06701, 75D30119C06703, 75D30119C06222, 75D30119C06225, and 75D30119C06010); and the <span class="named-content" data-type="funder">National Institute of Allergy and Infectious Diseases of the National Institutes of Health</span> under award numbers UM1 AI068634, UM1 AI068636, and UM1 AI106701. Sanofi donated rifapentine and all other trial drugs, supported the shipment of the trial drugs to all sites, and provided funding support for pharmacokinetic testing and preparation of the final clinical study report.</div><div role="paragraph">Dr. Martinson reports receiving grant support, paid to his institution, from Pfizer; and Dr. Chaisson, receiving consulting fees from Sanofi. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the trial participants who contributed their time to this trial and the local tuberculosis program staff who assisted in the clinical management of some trial participants; Phil LoBue, Carla Winston, and Jonathan Mermin for their continued support of the Tuberculosis Trials Consortium within the CDC; the staff at Westat and PPD for on-site monitoring; Charles M. Heilig for statistical support during the development of the protocol; William J. Burman for scientific contributions in the early development of the protocol; and Janet Anderson, Michael Chen, Cynthia Lee, Pei-Jean Feng, Courtney Fletcher, Richard Hafner, Jose M. Miro, Sachiko Miyahara, Kathleen Robergeau, and Lisa Wolf for contributions to the trial protocol.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2033400_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033400/suppl_file/nejmoa2033400_research-summary.pdf" download="nejmoa2033400_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033400_research-summary.pdf" data-doi="10.1056/NEJMoa2033400">Download</a></li><li>387.78 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2033400_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033400/suppl_file/nejmoa2033400_protocol.pdf" download="nejmoa2033400_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033400_protocol.pdf" data-doi="10.1056/NEJMoa2033400">Download</a></li><li>5.95 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2033400_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033400/suppl_file/nejmoa2033400_appendix.pdf" download="nejmoa2033400_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033400_appendix.pdf" data-doi="10.1056/NEJMoa2033400">Download</a></li><li>8.94 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2033400_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033400/suppl_file/nejmoa2033400_disclosures.pdf" download="nejmoa2033400_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033400_disclosures.pdf" data-doi="10.1056/NEJMoa2033400">Download</a></li><li>538.56 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2033400_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033400/suppl_file/nejmoa2033400_data-sharing.pdf" download="nejmoa2033400_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033400_data-sharing.pdf" data-doi="10.1056/NEJMoa2033400">Download</a></li><li>72.13 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <em>Clin Infect Dis</em> 2016;63:853-867.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciw566" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27621353/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000386041100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Executive+summary%3A+official+American+Thoracic+Society%2FCenters+for+Disease+Control+and+Prevention%2FInfectious+Diseases+Society+of+America+clinical+practice+guidelines%3A+treatment+of+drug-susceptible+tuberculosis.&amp;publication_year=2016&amp;journal=Clin+Infect+Dis&amp;pages=853-867&amp;doi=10.1093%2Fcid%2Fciw566&amp;pmid=27621353" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing adverse drug effects and costs. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] weeks of once-daily rifampin and isoniazid. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] doses adjusted for body weight (Table S1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] was administered on an empty stomach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, April 2017 (<a href="https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/">https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+treatment+of+drug-susceptible+tuberculosis+and+patient+care%2C+2017+update&amp;publication_year=2017" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing adverse drug effects and costs. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] weeks of once-daily rifampin and isoniazid. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more — effective tuberculosis vaccines, drugs, and diagnostics. <em>Proc Natl Acad Sci U S A</em> 2009;106:13980-13985.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0901720106" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19666590/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269078700065" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiological+benefits+of+more+%E2%80%94+effective+tuberculosis+vaccines%2C+drugs%2C+and+diagnostics.&amp;publication_year=2009&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=13980-13985&amp;doi=10.1073%2Fpnas.0901720106&amp;pmid=19666590" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Bonnett LJ, Ken-Dror G, Koh GCKW, Davies GR. Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early-phase clinical trials. <em>Clin Infect Dis</em> 2017;65:46-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/cix247" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28402396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403459300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+the+efficacy+of+drug+regimens+for+pulmonary+tuberculosis%3A+meta-analysis+of+endpoints+in+early-phase+clinical+trials.&amp;publication_year=2017&amp;journal=Clin+Infect+Dis&amp;pages=46-54&amp;doi=10.1093%2Fcid%2Fcix247&amp;pmid=28402396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics–pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. <em>Antimicrob Agents Chemother</em> 2003;47:2118-2124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.47.7.2118-2124.2003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12821456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000183786700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics%E2%80%93pharmacodynamics+of+rifampin+in+an+aerosol+infection+model+of+tuberculosis.&amp;publication_year=2003&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2118-2124&amp;doi=10.1128%2FAAC.47.7.2118-2124.2003&amp;pmid=12821456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Svensson EM, Svensson RJ, Te Brake LHM, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. <em>Clin Infect Dis</em> 2018;67:34-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciy026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29917079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438446600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+potential+for+treatment+shortening+with+higher+rifampicin+doses%3A+relating+drug+exposure+to+treatment+response+in+patients+with+pulmonary+tuberculosis.&amp;publication_year=2018&amp;journal=Clin+Infect+Dis&amp;pages=34-41&amp;doi=10.1093%2Fcid%2Fciy026&amp;pmid=29917079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Savic RM, Weiner M, MacKenzie WR, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. <em>Clin Pharmacol Ther</em> 2017;102:321-331.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cpt.634" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28124478/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405679600035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+the+optimal+dose+of+rifapentine+for+pulmonary+tuberculosis%3A+exposure-response+relations+from+two+phase+II+clinical+trials.&amp;publication_year=2017&amp;journal=Clin+Pharmacol+Ther&amp;pages=321-331&amp;doi=10.1002%2Fcpt.634&amp;pmid=28124478" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduction in bacillary burden. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and moxifloxacin at a daily dose of 400 mg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] likely to be feasible in most settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. <em>Clin Pharmacokinet</em> 2001;40:327-341.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2165/00003088-200140050-00002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11432536/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000169347200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+pharmacokinetics+and+pharmacodynamics+of+the+rifamycin+antibacterials.&amp;publication_year=2001&amp;journal=Clin+Pharmacokinet&amp;pages=327-341&amp;doi=10.2165%2F00003088-200140050-00002&amp;pmid=11432536" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] facilitates the completion of treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the rifamycin used in each trial regimen. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Rodríguez JC, Ruiz M, López M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against mycobacterium tuberculosis. <em>Int J Antimicrob Agents</em> 2002;20:464-467.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0924-8579(02)00239-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12458143/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000179899100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+activity+of+moxifloxacin%2C+levofloxacin%2C+gatifloxacin+and+linezolid+against+mycobacterium+tuberculosis.&amp;publication_year=2002&amp;journal=Int+J+Antimicrob+Agents&amp;pages=464-467&amp;doi=10.1016%2FS0924-8579%2802%2900239-X&amp;pmid=12458143" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against mycobacterium tuberculosis. <em>Antimicrob Agents Chemother</em> 1998;42:2066-2069.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.42.8.2066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9687408/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075131800032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+and+in+vivo+activities+of+moxifloxacin+and+clinafloxacin+against+mycobacterium+tuberculosis.&amp;publication_year=1998&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2066-2069&amp;doi=10.1128%2FAAC.42.8.2066&amp;pmid=9687408" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2004;169:421-426.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200310-1380OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14578218/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000188417800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin-containing+regimen+greatly+reduces+time+to+culture+conversion+in+murine+tuberculosis.&amp;publication_year=2004&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=421-426&amp;doi=10.1164%2Frccm.200310-1380OC&amp;pmid=14578218" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2004;170:1131-1134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200407-885OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15306535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000225076700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin-containing+regimens+of+reduced+duration+produce+a+stable+cure+in+murine+tuberculosis.&amp;publication_year=2004&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1131-1134&amp;doi=10.1164%2Frccm.200407-885OC&amp;pmid=15306535" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. <em>Am J Respir Crit Care Med</em> 2006;174:331-338.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200603-360OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16675781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239415200018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin+versus+ethambutol+in+the+first+2+months+of+treatment+for+pulmonary+tuberculosis.&amp;publication_year=2006&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=331-338&amp;doi=10.1164%2Frccm.200603-360OC&amp;pmid=16675781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. <em>Lancet</em> 2009;373:1183-1189.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(09)60333-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19345831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264940600032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin+versus+ethambutol+in+the+initial+treatment+of+tuberculosis%3A+a+double-blind%2C+randomised%2C+controlled+phase+II+trial.&amp;publication_year=2009&amp;journal=Lancet&amp;pages=1183-1189&amp;doi=10.1016%2FS0140-6736%2809%2960333-0&amp;pmid=19345831" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. <em>Int J Tuberc Lung Dis</em> 2008;12:128-138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18230244/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252493800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+II+study+of+the+sterilising+activities+of+ofloxacin%2C+gatifloxacin+and+moxifloxacin+in+pulmonary+tuberculosis.&amp;publication_year=2008&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=128-138&amp;pmid=18230244" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. <em>N Engl J Med</em> 2014;371:1577-1587.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1407426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25196020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+moxifloxacin-based+regimens+for+drug-sensitive+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1577-1587&amp;doi=10.1056%2FNEJMoa1407426&amp;pmid=25196020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to shorten therapy to 4 months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and a two-sided type I error rate of 5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r40" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involved mostly hospitalized patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. <em>Am J Respir Crit Care Med</em> 2009;180:273-280.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200901-0078OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19406981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268696000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Substitution+of+moxifloxacin+for+isoniazid+during+intensive+phase+treatment+of+pulmonary+tuberculosis.&amp;publication_year=2009&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=273-280&amp;doi=10.1164%2Frccm.200901-0078OC&amp;pmid=19406981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Conde MB, Mello FCQ, Duarte RS, et al. A phase 2 randomized trial of a rifapentine plus moxifloxacin-based regimen for treatment of pulmonary tuberculosis. <em>PLoS One</em> 2016;11(5):e0154778-e0154778.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0154778" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27159505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376576700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2+randomized+trial+of+a+rifapentine+plus+moxifloxacin-based+regimen+for+treatment+of+pulmonary+tuberculosis.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0154778-e0154778&amp;doi=10.1371%2Fjournal.pone.0154778&amp;pmid=27159505" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Williams K, Tyagi S, et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2005;172:1457-1462.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200507-1072OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16141439/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233697300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Weekly+moxifloxacin+and+rifapentine+is+more+active+than+the+Denver+regimen+in+murine+tuberculosis.&amp;publication_year=2005&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1457-1462&amp;doi=10.1164%2Frccm.200507-1072OC&amp;pmid=16141439" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? <em>Am J Respir Crit Care Med</em> 2008;178:989-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200807-1029OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18723432/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260611600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Isoniazid+or+moxifloxacin+in+rifapentine-based+regimens+for+experimental+tuberculosis%3F&amp;publication_year=2008&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=989-993&amp;doi=10.1164%2Frccm.200807-1029OC&amp;pmid=18723432" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. <em>PLoS Med</em> 2007;4(12):e344-e344.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.0040344" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18092886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000251874600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daily+dosing+of+rifapentine+cures+tuberculosis+in+three+months+or+less+in+the+murine+model.&amp;publication_year=2007&amp;journal=PLoS+Med&amp;pages=e344-e344&amp;doi=10.1371%2Fjournal.pmed.0040344&amp;pmid=18092886" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial. <em>Am J Respir Crit Care Med</em> 2015;191:333-343.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201410-1843OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25489785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348827000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daily+rifapentine+for+treatment+of+pulmonary+tuberculosis%3A+a+randomized%2C+dose-ranging+trial.&amp;publication_year=2015&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=333-343&amp;doi=10.1164%2Frccm.201410-1843OC&amp;pmid=25489785" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] time of completion of the intensive phase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and moxifloxacin at a daily dose of 400 mg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] was administered on an empty stomach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] with the result in a phase 2 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] likely to be feasible in most settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Nahid P, Kurbatova EV, et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. <em>Contemp Clin Trials</em> 2020;90:105938-105938.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2020.105938" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31981713/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527917400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+or+without+moxifloxacin+for+shortening+treatment+of+pulmonary+tuberculosis%3A+study+protocol+for+TBTC+study+31%2FACTG+A5349+phase+3+clinical+trial.&amp;publication_year=2020&amp;journal=Contemp+Clin+Trials&amp;pages=105938-105938&amp;doi=10.1016%2Fj.cct.2020.105938&amp;pmid=31981713" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of the trial have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 1200 mg once daily, and efavirenz. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] according to 20 key elements (Table S16). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] might not be responding well to treatment. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. <em>Am J Respir Crit Care Med</em> 2011;184:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201103-0536OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21836139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296613900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multisite+assessment+of+the+quantitative+capabilities+of+the+Xpert+MTB%2FRIF+assay.&amp;publication_year=2011&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1076-1084&amp;doi=10.1164%2Frccm.201103-0536OC&amp;pmid=21836139" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. <em>J Clin Microbiol</em> 2011;49:2827-2831.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JCM.00138-11" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21653771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293221900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suitability+of+Xpert+MTB%2FRIF+and+genotype+MTBDRplus+for+patient+selection+for+a+tuberculosis+clinical+trial.&amp;publication_year=2011&amp;journal=J+Clin+Microbiol&amp;pages=2827-2831&amp;doi=10.1128%2FJCM.00138-11&amp;pmid=21653771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Soares JF, Wu CFJ. Some restricted randomization rules in sequential designs. <em>Commun Stat Theory Methods</em> 1983;12:2017-2034.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03610928308828586" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1983RD26100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Some+restricted+randomization+rules+in+sequential+designs.&amp;publication_year=1983&amp;journal=Commun+Stat+Theory+Methods&amp;pages=2017-2034&amp;doi=10.1080%2F03610928308828586" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. <em>Antimicrob Agents Chemother</em> 2010;54:3390-3394.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.00345-10" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20516273/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000279963300039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+four+different+meal+types+on+the+population+pharmacokinetics+of+single-dose+rifapentine+in+healthy+male+volunteers.&amp;publication_year=2010&amp;journal=Antimicrob+Agents+Chemother&amp;pages=3390-3394&amp;doi=10.1128%2FAAC.00345-10&amp;pmid=20516273" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] was administered on an empty stomach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the rifamycin used in each trial regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] improved in the presence of high-fat foods. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. <em>Chest</em> 1999;115:12-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.115.1.12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9925057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000078074200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+of+rifampin+under+fasting+conditions%2C+with+food%2C+and+with+antacids.&amp;publication_year=1999&amp;journal=Chest&amp;pages=12-18&amp;doi=10.1378%2Fchest.115.1.12&amp;pmid=9925057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Witney AA, Bateson ALE, Jindani A, et al. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. <em>BMC Med</em> 2017;15:71-71.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12916-017-0834-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28351427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397679000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+whole-genome+sequencing+to+distinguish+relapse+from+reinfection+in+a+completed+tuberculosis+clinical+trial.&amp;publication_year=2017&amp;journal=BMC+Med&amp;pages=71-71&amp;doi=10.1186%2Fs12916-017-0834-4&amp;pmid=28351427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PPJ, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. <em>Int J Tuberc Lung Dis</em> 2010;14:241-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20074418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274033300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Timing+of+relapse+in+short-course+chemotherapy+trials+for+tuberculosis.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=241-242&amp;pmid=20074418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">The common terminology criteria for adverse events, version 4.03. Bethesda, MD: National Institutes of Health, June 14, 2010 (<a href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r31" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+common+terminology+criteria+for+adverse+events%2C+version+4.03&amp;publication_year=2010" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r31" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Terminology Criteria for Adverse Events. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r31-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] Terminology Criteria for Adverse Events. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <em>N Engl J Med</em> 2014;371:1599-1608.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r32" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1314210&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+moxifloxacin+for+pulmonary+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1599-1608&amp;doi=10.1056%2FNEJMoa1314210&amp;pmid=25337749" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r32" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and a two-sided type I error rate of 5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r40" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] involved mostly hospitalized patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. <em>N Engl J Med</em> 2014;371:1588-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1315817&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+four-month+gatifloxacin-containing+regimen+for+treating+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1588-1598&amp;doi=10.1056%2FNEJMoa1315817&amp;pmid=25337748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Mohamed K, Embleton A, Cuffe RL. Adjusting for covariates in non-inferiority studies with margins defined as risk differences. <em>Pharm Stat</em> 2011;10:461-466.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pst.520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21956950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295873100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adjusting+for+covariates+in+non-inferiority+studies+with+margins+defined+as+risk+differences.&amp;publication_year=2011&amp;journal=Pharm+Stat&amp;pages=461-466&amp;doi=10.1002%2Fpst.520&amp;pmid=21956950" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Lumb R, Van Deun A, Bastian I, Fitz-Gerald M. <em>Laboratory diagnosis of tuberculosis by sputum microscopy: the handbook, global edition.</em> Adelaide, Australia: SA Pathology, 2013 (<a href="http://www.stoptb.org/wg/gli/assets/documents/TB%20MICROSCOPY%20HANDBOOK_FINAL.pdf">http://www.stoptb.org/wg/gli/assets/documents/TB%20MICROSCOPY%20HANDBOOK_FINAL.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Laboratory+diagnosis+of+tuberculosis+by+sputum+microscopy%3A+the+handbook%2C+global+edition.&amp;publication_year=2013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Reuben A. Hy’s law. <em>Hepatology</em> 2004;39:574-578.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.20081" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14768020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000220375600043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hy%E2%80%99s+law.&amp;publication_year=2004&amp;journal=Hepatology&amp;pages=574-578&amp;doi=10.1002%2Fhep.20081&amp;pmid=14768020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Fig. S9). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] levels or who met the criteria of Hy’s law. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. <em>Gut</em> 1972;13:366-371.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gut.13.5.366" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/5036092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972M829200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+rifampicin+on+liver+function+in+man.&amp;publication_year=1972&amp;journal=Gut&amp;pages=366-371&amp;doi=10.1136%2Fgut.13.5.366&amp;pmid=5036092" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. <em>Am J Respir Crit Care Med</em> 2006;174:935-952.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200510-1666ST" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17021358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241259000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+official+ATS+statement%3A+hepatotoxicity+of+antituberculosis+therapy.&amp;publication_year=2006&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=935-952&amp;doi=10.1164%2Frccm.200510-1666ST&amp;pmid=17021358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. <em>Clin Infect Dis</em> 2005;41:Suppl 2:S144-S157.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/428055" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15942881/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229891100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antimicrobial+safety%3A+focus+on+fluoroquinolones.&amp;publication_year=2005&amp;journal=Clin+Infect+Dis&amp;pages=S144-S157&amp;doi=10.1086%2F428055&amp;pmid=15942881" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Fox W. Whither short-course chemotherapy? <em>Br J Dis Chest</em> 1981;75:331-357.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0007-0971(81)90022-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7030377/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whither+short-course+chemotherapy%3F&amp;publication_year=1981&amp;journal=Br+J+Dis+Chest&amp;pages=331-357&amp;doi=10.1016%2F0007-0971%2881%2990022-X&amp;pmid=7030377" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="r41" class="citations"><div class="citation"><div class="citation-content">Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. <em>Curr Opin Pharmacol</em> 2018;42:7-15.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.coph.2018.05.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29885623/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450382700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Drug-resistant+tuberculosis%3A+challenges+and+opportunities+for+diagnosis+and+treatment.&amp;publication_year=2018&amp;journal=Curr+Opin+Pharmacol&amp;pages=7-15&amp;doi=10.1016%2Fj.coph.2018.05.013&amp;pmid=29885623" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="r42" class="citations"><div class="citation"><div class="citation-content">Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. <em>N Engl J Med</em> 2017;377:1043-1054.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_43_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1614915&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28902596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410545200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+rapid+molecular+drug-susceptibility+test+for+tuberculosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1043-1054&amp;doi=10.1056%2FNEJMoa1614915&amp;pmid=28902596" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/18"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">18</span></span> • <span property="datePublished">May 6, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1705</span>-<span property="pageEnd">1718</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2033400" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2033400?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 5, 2021</div><div><b class="core-label">Published in issue</b>: May 6, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/bacterial-infections" alt="View article keyword Bacterial Infections" data-interactiontype="article_recirculation_click">Bacterial Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/tuberculosis" alt="View article keyword Tuberculosis" data-interactiontype="article_recirculation_click">Tuberculosis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Susan E.</span> <span property="familyName">Dorman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Payam</span> <span property="familyName">Nahid</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2811-1311" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2811-1311</a></span>, <span property="author" typeof="Person"><span property="givenName">Ekaterina V.</span> <span property="familyName">Kurbatova</span>, <span property="honorificSuffix">M.D., Ph.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patrick P.J.</span> <span property="familyName">Phillips</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kia</span> <span property="familyName">Bryant</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kelly E.</span> <span property="familyName">Dooley</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Melissa</span> <span property="familyName">Engle</span>, <span property="honorificSuffix">C.R.T., C.C.R.C.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stefan V.</span> <span property="familyName">Goldberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ha T.T.</span> <span property="familyName">Phan</span>, <span property="honorificSuffix">Dr.P.H., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James</span> <span property="familyName">Hakim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John L.</span> <span property="familyName">Johnson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Madeleine</span> <span property="familyName">Lourens</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Neil A.</span> <span property="familyName">Martinson</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Grace</span> <span property="familyName">Muzanyi</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kim</span> <span property="familyName">Narunsky</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandy</span> <span property="familyName">Nerette</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nhung V.</span> <span property="familyName">Nguyen</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thuong H.</span> <span property="familyName">Pham</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Samuel</span> <span property="familyName">Pierre</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anne E.</span> <span property="familyName">Purfield</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wadzanai</span> <span property="familyName">Samaneka</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Radojka M.</span> <span property="familyName">Savic</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ian</span> <span property="familyName">Sanne</span>, <span property="honorificSuffix">M.B., B.Ch., D.T.M.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nigel A.</span> <span property="familyName">Scott</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Justin</span> <span property="familyName">Shenje</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Erin</span> <span property="familyName">Sizemore</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Vernon</span>, <span property="honorificSuffix">M.D., M.H.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ziyaad</span> <span property="familyName">Waja</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marc</span> <span property="familyName">Weiner</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Susan</span> <span property="familyName">Swindells</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Richard E.</span> <span property="familyName">Chaisson</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium</span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Medical University of South Carolina, Charleston (S.E.D.); the UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco (P.N., P.P.J.P., R.M.S.); the Vietnam National Tuberculosis Program–University of California, San Francisco Research Collaboration Unit (P.N., P.P.J.P., H.T.T.P., N.V.N., T.H.P., R.M.S.) and the National Lung Hospital (N.V.N., T.H.P.) — both in Hanoi; the Centers for Disease Control and Prevention, Atlanta (E.V.K., K.B., S.V.G., A.E.P., N.A.S., E.S., A.V.); the University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio (M.E., M.W.); the University of Zimbabwe College of Health Sciences, Harare (J.H., W.S.); Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland (J.L.J.); the Uganda–Case Western Reserve University Research Collaboration, Kampala (J.L.J., G.M.); TASK (M.L.), the University of Cape Town Lung Institute (K.N.), and the South African Tuberculosis Vaccine Initiative (J.S.), Cape Town, the Perinatal HIV Research Unit, University of the Witwatersrand (N.A.M., Z.W.), and the Wits Health Consortium (I.S.), Johannesburg — all in South Africa; Johns Hopkins University School of Medicine, Baltimore (K.E.D., N.A.M., R.E.C.), and the U.S. Public Health Service Commissioned Corps, Rockville (A.E.P.) — both in Maryland; the Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince (S.N., S.P.); and the University of Nebraska Medical Center, Omaha (S.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Nahid at the UCSF Center for Tuberculosis, University of California, San Francisco, 1001 Potrero Ave. 5K1, San Francisco, CA 94110, or at <a href="mailto:pnahid@ucsf.edu">pnahid@ucsf.edu</a>.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Drs. Dorman, Nahid, and Kurbatova contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">328</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2033400" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="ba461236-1c83-5c6e-e16e-c8b38ba60c07"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854" style="display:inline-block;">
                <img alt="Article has an altmetric score of 845" src="https://badges.altmetric.com/?size=320&amp;score=845&amp;types=mbctfud1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_ba461236-1c83-5c6e-e16e-c8b38ba60c07" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=news">
          Picked up by <b>43</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=policy-documents">
          Referenced in <b>3</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=twitter">
          Posted by <b>712</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=facebook">
          On <b>10</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=guidelines">
          Referenced in <b>6</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=105361854&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>603</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d67cdc554fa432-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2033400"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-18%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2033400%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="328" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John W. Wilson, </li><li class="list-inline-item cited-by__entry__author">Zelalem Temesgen, </li><li class="list-inline-item cited-by__entry__author">James T. Gaensbauer, </li></ul><span class="cited-by__entry__title">Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis, </span><span class="cited-by__entry__series-title">Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, </span><span class="cited-by__entry__volume"><strong>40</strong>, </span><span class="cited-by__entry__page-range">(100536), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jctube.2025.100536" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jctube.2025.100536</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jctube.2025.100536" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Munechika Hara, </li><li class="list-inline-item cited-by__entry__author">Toshitsugu Yashiro, </li><li class="list-inline-item cited-by__entry__author">Yasuaki Yashiro, </li></ul><span class="cited-by__entry__title">Delayed diagnosis of pulmonary tuberculosis with pleuritis due to ampicillin/sulbactam: A case report, </span><span class="cited-by__entry__series-title">World Journal of Clinical Cases, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">19, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.12998/wjcc.v13.i19.104083" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.12998/wjcc.v13.i19.104083</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.12998/wjcc.v13.i19.104083" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Athanassios Giannis, </li><li class="list-inline-item cited-by__entry__author">Athanassios Giannis, </li></ul><span class="cited-by__entry__title">Streptomycin, PAS, and the Death of the “Captain of Death”, </span><span class="cited-by__entry__series-title">Natural Compounds Enabled Therapies, </span><span class="cited-by__entry__page-range">(25-47), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/978-3-031-94024-8_2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-3-031-94024-8_2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-3-031-94024-8_2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nusrat Shafiq, </li><li class="list-inline-item cited-by__entry__author">Ashok Kumar, </li><li class="list-inline-item cited-by__entry__author">Vikram Vohra, </li><li class="list-inline-item cited-by__entry__author">Gopal Krishan Khuller, </li><li class="list-inline-item cited-by__entry__author">Manjula Singh, </li><li class="list-inline-item cited-by__entry__author">Amandeep Kaur, </li><li class="list-inline-item cited-by__entry__author">Narinder Gulati, </li><li class="list-inline-item cited-by__entry__author">Vishal Chopra, </li><li class="list-inline-item cited-by__entry__author">Aditi Gupta, </li><li class="list-inline-item cited-by__entry__author">Sandeep Kaushal, </li><li class="list-inline-item cited-by__entry__author">Akashdeep Singh, </li><li class="list-inline-item cited-by__entry__author">A N Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Ritin Mohindra, </li><li class="list-inline-item cited-by__entry__author">Rajesh Raju, </li><li class="list-inline-item cited-by__entry__author">Honney Sawhney, </li><li class="list-inline-item cited-by__entry__author">Divya Goel, </li><li class="list-inline-item cited-by__entry__author">Alkesh Kumar Khurana, </li><li class="list-inline-item cited-by__entry__author">Sagar Khadanga, </li><li class="list-inline-item cited-by__entry__author">Ashok Bansal, </li><li class="list-inline-item cited-by__entry__author">Pavan Malhotra, </li><li class="list-inline-item cited-by__entry__author">Anil K Gupta, </li><li class="list-inline-item cited-by__entry__author">Dinesh Kansal, </li><li class="list-inline-item cited-by__entry__author">Devendra Singh Dadhwal, </li><li class="list-inline-item cited-by__entry__author">Sunil Sethi, </li><li class="list-inline-item cited-by__entry__author">Varinder K Saini, </li><li class="list-inline-item cited-by__entry__author">Deepak Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Parvinder Jit Singh, </li><li class="list-inline-item cited-by__entry__author">Madhu Sabharwal, </li><li class="list-inline-item cited-by__entry__author">Lokender Kumar, </li><li class="list-inline-item cited-by__entry__author">Khalid Umer Khayyam, </li><li class="list-inline-item cited-by__entry__author">Dipti Kushwaha, </li><li class="list-inline-item cited-by__entry__author">Vidhu Mittal, </li><li class="list-inline-item cited-by__entry__author">Samriti Jain, </li><li class="list-inline-item cited-by__entry__author">Bharath A Chhabria, </li><li class="list-inline-item cited-by__entry__author">Sandeep Kaur, </li><li class="list-inline-item cited-by__entry__author">Abhishek Taneja, </li><li class="list-inline-item cited-by__entry__author">Prashant Pathak, </li><li class="list-inline-item cited-by__entry__author">Abhinav Gupta, </li><li class="list-inline-item cited-by__entry__author">Rajat Bral, </li><li class="list-inline-item cited-by__entry__author">Ajay Kumar, </li><li class="list-inline-item cited-by__entry__author">Ritika Kondel Bhandari, </li><li class="list-inline-item cited-by__entry__author">Avaneesh Kumar Pandey, </li><li class="list-inline-item cited-by__entry__author">Imraan Rather, </li><li class="list-inline-item cited-by__entry__author">Samir Malhotra, </li></ul><span class="cited-by__entry__title">Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial, </span><span class="cited-by__entry__series-title">Journal of Antimicrobial Chemotherapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/jac/dkaf176" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/jac/dkaf176</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/jac/dkaf176" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Heena Soni, </li><li class="list-inline-item cited-by__entry__author">Sandeep Tyagi, </li><li class="list-inline-item cited-by__entry__author">Kishor Mane, </li><li class="list-inline-item cited-by__entry__author">Anil M. Shelke, </li><li class="list-inline-item cited-by__entry__author">Pradeep Kumar, </li><li class="list-inline-item cited-by__entry__author">Firat Kaya, </li><li class="list-inline-item cited-by__entry__author">David Alland, </li><li class="list-inline-item cited-by__entry__author">Matthew Zimmerman, </li><li class="list-inline-item cited-by__entry__author">Joel S. Freundlich, </li><li class="list-inline-item cited-by__entry__author">Eric L. Nuermberger, </li></ul><span class="cited-by__entry__title">The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis, </span><span class="cited-by__entry__series-title">Antimicrobial Agents and Chemotherapy, </span><span class="cited-by__entry__volume"><strong>69</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1128/aac.00130-25" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/aac.00130-25</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/aac.00130-25" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nicolas A. Menzies, </li><li class="list-inline-item cited-by__entry__author">Suzanne M. Marks, </li><li class="list-inline-item cited-by__entry__author">Yuli L. Hsieh, </li><li class="list-inline-item cited-by__entry__author">Nicole A. Swartwood, </li><li class="list-inline-item cited-by__entry__author">Garrett R. Beeler Asay, </li><li class="list-inline-item cited-by__entry__author">Jacek Skarbinski, </li><li class="list-inline-item cited-by__entry__author">C. Robert Horsburgh, </li><li class="list-inline-item cited-by__entry__author">Ted Cohen, </li></ul><span class="cited-by__entry__title">Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015–2019, </span><span class="cited-by__entry__series-title">American Journal of Respiratory and Critical Care Medicine, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1059-1068), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1164/rccm.202411-2213OC" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1164/rccm.202411-2213OC</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1164/rccm.202411-2213OC" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ying Wang, </li><li class="list-inline-item cited-by__entry__author">Daxing Cao, </li><li class="list-inline-item cited-by__entry__author">Guihua Liu, </li></ul><span class="cited-by__entry__title">Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress, </span><span class="cited-by__entry__series-title">Microbial Pathogenesis, </span><span class="cited-by__entry__page-range">(107794), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.micpath.2025.107794" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.micpath.2025.107794</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.micpath.2025.107794" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">F. Vuotto, </li><li class="list-inline-item cited-by__entry__author">J.P. Bru, </li><li class="list-inline-item cited-by__entry__author">E. Canoui, </li><li class="list-inline-item cited-by__entry__author">M. Caseris, </li><li class="list-inline-item cited-by__entry__author">M.C.C. Chopin, </li><li class="list-inline-item cited-by__entry__author">R. Cohen, </li><li class="list-inline-item cited-by__entry__author">S. Diamantis, </li><li class="list-inline-item cited-by__entry__author">A. Dinh, </li><li class="list-inline-item cited-by__entry__author">P. Fillatre, </li><li class="list-inline-item cited-by__entry__author">R. Gauzit, </li><li class="list-inline-item cited-by__entry__author">Y. Gillet, </li><li class="list-inline-item cited-by__entry__author">A.P. Jonville-Bera, </li><li class="list-inline-item cited-by__entry__author">M. Lafaurie, </li><li class="list-inline-item cited-by__entry__author">P. Lesprit, </li><li class="list-inline-item cited-by__entry__author">M. Lorrot, </li><li class="list-inline-item cited-by__entry__author">J. Lourtet, </li><li class="list-inline-item cited-by__entry__author">L. Maulin, </li><li class="list-inline-item cited-by__entry__author">D. Poitrenaud, </li><li class="list-inline-item cited-by__entry__author">A. Pariente, </li><li class="list-inline-item cited-by__entry__author">J. Raymond, </li><li class="list-inline-item cited-by__entry__author">C. Strady, </li><li class="list-inline-item cited-by__entry__author">J.P. Stahl, </li><li class="list-inline-item cited-by__entry__author">E. Varon, </li><li class="list-inline-item cited-by__entry__author">Y. Welker, </li><li class="list-inline-item cited-by__entry__author">E. Bonnet, </li></ul><span class="cited-by__entry__title">The latest updates on the proper use of fluoroquinolones – Actualisation 2025 update by the SPILF and the GPIP, </span><span class="cited-by__entry__series-title">Infectious Diseases Now, </span><span class="cited-by__entry__volume"><strong>55</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(105062), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.idnow.2025.105062" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.idnow.2025.105062</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.idnow.2025.105062" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Katie Wright, </li></ul><span class="cited-by__entry__title">Tackling Tuberculosis: The Current Landscape and Future Directions, </span><span class="cited-by__entry__series-title">EMJ Microbiology &amp; Infectious Diseases, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rūta Mereškevičienė, </li><li class="list-inline-item cited-by__entry__author">Edvardas Danila, </li></ul><span class="cited-by__entry__title">The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review, </span><span class="cited-by__entry__series-title">Medicina, </span><span class="cited-by__entry__volume"><strong>61</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(911), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/medicina61050911" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/medicina61050911</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/medicina61050911" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-18%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2033400%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033400" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2033400" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033400.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f0.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/1a13f36b-26f4-4027-a8a6-75d141538758/assets/images/large/nejmoa2033400_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f1.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/6d56e303-6e87-4c44-9ea8-1166a19e1618/assets/images/large/nejmoa2033400_f1.jpg" height="2935" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">MTB denotes <i>Mycobacterium tuberculosis</i>.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f2.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/f32abf9b-efd9-42ad-ba9a-f6785d479fd2/assets/images/large/nejmoa2033400_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Primary and Secondary Efficacy Analyses and Time to an Unfavorable Outcome.</div><div class="notes"><div role="doc-footnote">Panel A shows the results of the primary efficacy analysis in the microbiologically eligible and the assessable analysis populations and of the secondary analyses in the intention-to-treat and the per-protocol analysis populations (top, rifapentine–moxifloxacin regimen vs. control regimen; bottom, rifapentine regimen vs. control regimen). The noninferiority margin of 6.6 percentage points is designated by the dashed vertical line. Participants were classified as having an unfavorable outcome if they had <i>M. tuberculosis</i>–positive cultures from two sputum specimens obtained at or after week 17 without an intervening negative culture, died or were withdrawn from the trial or lost to follow-up during the treatment period, had an <i>M. tuberculosis</i>–positive culture when last seen, died from tuberculosis during the post-treatment follow-up, or received additional treatment for tuberculosis. The microbiologically eligible analysis population included all the participants except those who had no evidence of <i>M. tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria; the participants with an outcome status that was not assessable were reclassified as having had an unfavorable outcome. The assessable analysis population included the participants in the microbiologically eligible population except those whose outcome status had been reclassified from not assessable to unfavorable. The per-protocol 75% and per-protocol 95% analysis populations included the participants in the assessable population, except those who did not complete 75% or 95% of the assigned treatment doses, respectively, unless the reason for inadequate treatment was death or bacteriologic treatment failure. Panel B shows the results for the time to unfavorable outcome for the microbiologically eligible population. Data were censored for the participants who could not be assessed. HIV denotes human immunodeficiency virus. The inset shows the same data on an expanded y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2033400/asset/45f30825-764c-42a4-a52e-5e69d75cc419/assets/images/large/nejmoa2033400_t1.jpg" height="2245" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Control<br>(N=768)</th><th class="txxx-borders">Rifapentine–Moxifloxacin<br>(N=791)</th><th class="txxx-borders">Rifapentine<br>(N=784)</th><th class="txxr-borders">Total<br>(N=2343)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Male sex — no./total no. (%)</td><td class="xxxx-borders shading">544/768 (71)</td><td class="xxxx-borders shading">563/791 (71)</td><td class="xxxx-borders shading">563/784 (72)</td><td class="xxxr-borders shading">1670/2343 (71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders">30.9 (13.7–77.5)</td><td class="xxxx-borders">31.0 (14.6–72.5)</td><td class="xxxx-borders">31.0 (14.1–81.4)</td><td class="xxxr-borders">31.0 (13.7–81.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age group — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">12–17 yr</td><td class="xxxx-borders">19/768 (2)</td><td class="xxxx-borders">25/791 (3)</td><td class="xxxx-borders">19/784 (2)</td><td class="xxxr-borders">63/2343 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18–35 yr</td><td class="xxxx-borders shading">479/768 (62)</td><td class="xxxx-borders shading">486/791 (61)</td><td class="xxxx-borders shading">485/784 (62)</td><td class="xxxr-borders shading">1450/2343 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&gt;35 yr</td><td class="xxxx-borders">270/768 (35)</td><td class="xxxx-borders">280/791 (35)</td><td class="xxxx-borders">280/784 (36)</td><td class="xxxr-borders">830/2343 (35)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no./total no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">86/765 (11)</td><td class="xxxx-borders">89/790 (11)</td><td class="xxxx-borders">93/783 (12)</td><td class="xxxr-borders">268/2338 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">553/765 (72)</td><td class="xxxx-borders shading">552/790 (70)</td><td class="xxxx-borders shading">571/783 (73)</td><td class="xxxr-borders shading">1676/2338 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">15/765 (2)</td><td class="xxxx-borders">13/790 (2)</td><td class="xxxx-borders">8/783 (1)</td><td class="xxxr-borders">36/2338 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Multiracial</td><td class="xxxx-borders shading">111/765 (15)</td><td class="xxxx-borders shading">136/790 (17)</td><td class="xxxx-borders shading">111/783 (14)</td><td class="xxxr-borders shading">358/2338 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">HIV positivity — no./total no. (%)</td><td class="xxxx-borders">64/768 (8)</td><td class="xxxx-borders">62/791 (8)</td><td class="xxxx-borders">68/784 (9)</td><td class="xxxr-borders">194/2343 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median CD4 count among those with HIV positivity (IQR)</td><td class="xxxx-borders shading">334 (249–485)</td><td class="xxxx-borders shading">346 (253–458)</td><td class="xxxx-borders shading">351 (221–437)</td><td class="xxxr-borders shading">344 (223–455)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cavitation on chest radiography — no./total no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">206/768 (27)</td><td class="xxxx-borders shading">213/791 (27)</td><td class="xxxx-borders shading">206/784 (26)</td><td class="xxxr-borders shading">625/2343 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;4 cm</td><td class="xxxx-borders">251/768 (33)</td><td class="xxxx-borders">277/791 (35)</td><td class="xxxx-borders">246/784 (31)</td><td class="xxxr-borders">774/2343 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥4 cm</td><td class="xxxx-borders shading">307/768 (40)</td><td class="xxxx-borders shading">295/791 (37)</td><td class="xxxx-borders shading">327/784 (42)</td><td class="xxxr-borders shading">929/2343 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body weight — kg</td><td class="xxxx-borders">52.0</td><td class="xxxx-borders">53.0</td><td class="xxxx-borders">53.3</td><td class="xxxr-borders">53.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO smear grade — no./total no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a><a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">21/766 (2.7)</td><td class="xxxx-borders">31/789 (3.9)</td><td class="xxxx-borders">36/782 (4.6)</td><td class="xxxr-borders">88/2337 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Scanty or 1–9 acid-fast bacilli</td><td class="xxxx-borders shading">121/766 (15.8)</td><td class="xxxx-borders shading">147/789 (18.6)</td><td class="xxxx-borders shading">124/782 (15.9)</td><td class="xxxr-borders shading">392/2337 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1+</td><td class="xxxx-borders">187/766 (24.4)</td><td class="xxxx-borders">168/789 (21.3)</td><td class="xxxx-borders">172/782 (22.0)</td><td class="xxxr-borders">527/2337 (22.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2+</td><td class="xxxx-borders shading">229/766 (29.9)</td><td class="xxxx-borders shading">228/789 (28.9)</td><td class="xxxx-borders shading">227/782 (29.0)</td><td class="xxxr-borders shading">684/2337 (29.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3+</td><td class="xxxx-borders">198/766 (25.8)</td><td class="xxxx-borders">209/789 (26.5)</td><td class="xxxx-borders">214/782 (27.4)</td><td class="xxxr-borders">621/2337 (26.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Positive smear, WHO scale not used<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">10/766 (1.3)</td><td class="xxxx-borders shading">6/789 (0.8)</td><td class="xxxx-borders shading">9/782 (1.2)</td><td class="xxxr-borders shading">25/2337 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (range)<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">18.9 (12.8–45.2)</td><td class="xxxx-borders">19.0 (14.1–39.1)</td><td class="xxxx-borders">18.9 (13.4–35.4)</td><td class="xxxr-borders">18.9 (12.8–45.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Current smoker — no./total no. (%)</td><td class="xxxx-borders shading">196/768 (26)</td><td class="xxxx-borders shading">175/791 (22)</td><td class="xxxx-borders shading">200/784 (26)</td><td class="xxxr-borders shading">571/2343 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Prior course of tuberculosis treatment — no./total no. (%)</td><td class="xbxx-borders">83/768 (11)</td><td class="xbxx-borders">97/791 (12)</td><td class="xbxx-borders">85/784 (11)</td><td class="xbxr-borders">265/2343 (11)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The microbiologically eligible population included all the participants except those who had no evidence of <i>Mycobacterium tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria. HIV denotes human immunodeficiency virus, and IQR interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the trial participants; information about race was not available for 5 participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Cavity size refers to the aggregate diameter of all cavities.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Sputum smears were not available for 6 participants.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><div class="label">¶</div></a><div id="core-t1fn5" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg">Sputum smears were graded according to the World Health Organization (WHO) classification, which provides different criteria for each grade depending on the type of microscopy and magnification used at the site laboratory.<sup></sup></a><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="core-body-ref-r35" href-manipulated="true" aria-label="Reference 35" data-to-manipulate="false">35</a></div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Participants at Baseline in the Microbiologically Eligible Population.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2033400/asset/b075d434-2885-4b8f-bd38-88d9fa13055b/assets/images/large/nejmoa2033400_t2.jpg" height="2334" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Microbiologically Eligible Population</span></th><th class="txxr-borders" colspan="4"><span>Assessable Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Control<br>(N=768)</th><th class="xxxx-borders">Rifapentine–Moxifloxacin<br>(N=791)</th><th class="xxxx-borders">Rifapentine<br>(N=784)</th><th class="xxxx-borders">Total<br>(N=2343)</th><th class="xxxx-borders">Control<br>(N=726)</th><th class="xxxx-borders">Rifapentine–Moxifloxacin<br>(N=756)</th><th class="xxxx-borders">Rifapentine<br>(N=752)</th><th class="xxxr-borders">Total<br>(N=2234)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Favorable</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders">656 (85.4)</td><td class="xxxx-borders">668 (84.5)</td><td class="xxxx-borders">645 (82.3)</td><td class="xxxx-borders">1969 (84.0)</td><td class="xxxx-borders">656 (90.4)</td><td class="xxxx-borders">668 (88.4)</td><td class="xxxx-borders">645 (85.8)</td><td class="xxxr-borders">1969 (88.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted difference from control — percentage points (95% CI)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">1.0 (−2.6 to 4.5)</td><td class="xxxx-borders shading">3.0 (−0.6 to 6.6)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">2.0 (−1.1 to 5.1)</td><td class="xxxx-borders shading">4.4 (1.2 to 7.7)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participant had negative culture at month 12 — no. (%)</td><td class="xxxx-borders">643 (83.7)</td><td class="xxxx-borders">656 (82.9)</td><td class="xxxx-borders">636 (81.1)</td><td class="xxxx-borders">1935 (82.6)</td><td class="xxxx-borders">643 (88.6)</td><td class="xxxx-borders">656 (86.8)</td><td class="xxxx-borders">636 (84.6)</td><td class="xxxr-borders">1935 (86.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participant was seen at month 12 but no sputum was produced or cultures were contaminated but without evidence of <i>M. tuberculosis</i> — no. (%)</td><td class="xxxx-borders shading">13 (1.7)</td><td class="xxxx-borders shading">12 (1.5)</td><td class="xxxx-borders shading">9 (1.1)</td><td class="xxxx-borders shading">34 (1.5)</td><td class="xxxx-borders shading">13 (1.8)</td><td class="xxxx-borders shading">12 (1.6)</td><td class="xxxx-borders shading">9 (1.2)</td><td class="xxxr-borders shading">34 (1.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Unfavorable</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders shading">112 (14.6)</td><td class="xxxx-borders shading">123 (15.5)</td><td class="xxxx-borders shading">139 (17.7)</td><td class="xxxx-borders shading">374 (16.0)</td><td class="xxxx-borders shading">70 (9.6)</td><td class="xxxx-borders shading">88 (11.6)</td><td class="xxxx-borders shading">107 (14.2)</td><td class="xxxr-borders shading">265 (11.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Outcome related to tuberculosis — no. (%)</td><td class="xxxx-borders">24 (3.1)</td><td class="xxxx-borders">45 (5.7)</td><td class="xxxx-borders">75 (9.6)</td><td class="xxxx-borders">144 (6.1)</td><td class="xxxx-borders">24 (3.3)</td><td class="xxxx-borders">45 (6.0)</td><td class="xxxx-borders">75 (10.0)</td><td class="xxxr-borders">144 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Two consecutive positive cultures at or after week 17<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">11 (1.4)</td><td class="xxxx-borders shading">34 (4.3)</td><td class="xxxx-borders shading">63 (8.0)</td><td class="xxxx-borders shading">108 (4.6)</td><td class="xxxx-borders shading">11 (1.5)</td><td class="xxxx-borders shading">34 (4.5)</td><td class="xxxx-borders shading">63 (8.4)</td><td class="xxxr-borders shading">108 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Participant not seen at month 12 but had positive culture when last seen</td><td class="xxxx-borders">11 (1.4)</td><td class="xxxx-borders">3 (0.4)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">18 (0.8)</td><td class="xxxx-borders">11 (1.5)</td><td class="xxxx-borders">3 (0.4)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxr-borders">18 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Clinical diagnosis of tuberculosis recurrence and treatment restarted</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">18 (0.8)</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">8 (1.1)</td><td class="xxxx-borders shading">8 (1.1)</td><td class="xxxr-borders shading">18 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Outcome not related to tuberculosis — no. (%)</td><td class="xxxx-borders">46 (6.0)</td><td class="xxxx-borders">43 (5.4)</td><td class="xxxx-borders">32 (4.1)</td><td class="xxxx-borders">121 (5.2)</td><td class="xxxx-borders">46 (6.3)</td><td class="xxxx-borders">43 (5.7)</td><td class="xxxx-borders">32 (4.3)</td><td class="xxxr-borders">121 (5.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Consent withdrawn during treatment period with no adverse event reported</td><td class="xxxx-borders shading">14 (1.8)</td><td class="xxxx-borders shading">15 (1.9)</td><td class="xxxx-borders shading">11 (1.4)</td><td class="xxxx-borders shading">40 (1.7)</td><td class="xxxx-borders shading">14 (1.9)</td><td class="xxxx-borders shading">15 (2.0)</td><td class="xxxx-borders shading">11 (1.5)</td><td class="xxxr-borders shading">40 (1.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change in treatment because of adverse event</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">16 (2.0)</td><td class="xxxx-borders">9 (1.1)</td><td class="xxxx-borders">33 (1.4)</td><td class="xxxx-borders">8 (1.1)</td><td class="xxxx-borders">16 (2.1)</td><td class="xxxx-borders">9 (1.2)</td><td class="xxxr-borders">33 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death during treatment period</td><td class="xxxx-borders shading">7 (0.9)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">13 (0.6)</td><td class="xxxx-borders shading">7 (1.0)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxr-borders shading">13 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Loss to follow-up during treatment period</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">12 (0.5)</td><td class="xxxx-borders">8 (1.1)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxx-borders">2 (0.3)</td><td class="xxxr-borders">12 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Consent withdrawn during treatment period after occurrence of adverse event</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">8 (0.3)</td><td class="xxxx-borders shading">2 (0.3)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxr-borders shading">8 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treatment changed or restarted for other reasons</td><td class="xxxx-borders">7 (0.9)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">15 (0.6)</td><td class="xxxx-borders">7 (1.0)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxr-borders">15 (0.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Not assessable</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with outcome — no. (%)</td><td class="xxxx-borders">42 (5.5)</td><td class="xxxx-borders">32 (4.0)</td><td class="xxxx-borders">35 (4.5)</td><td class="xxxx-borders">109 (4.7)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Participant not seen at month 12 but had negative culture when last seen</td><td class="xxxx-borders shading">31 (4.0)</td><td class="xxxx-borders shading">22 (2.8)</td><td class="xxxx-borders shading">23 (2.9)</td><td class="xxxx-borders shading">76 (3.2)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treatment discontinued because of pregnancy</td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">5 (0.6)</td><td class="xxxx-borders">4 (0.5)</td><td class="xxxx-borders">17 (0.7)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death unrelated to tuberculosis during follow-up</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">14 (0.6)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Violent or accidental death during treatment period</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.1)</td><td class="xxxx-borders">1 (&lt;0.1)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Exogenous reinfection confirmed on WGS</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">1 (0.1)</td><td class="xbxx-borders shading">1 (&lt;0.1)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">NA</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The assessable population included the participants in the microbiologically eligible population who met the criteria for favorable or unfavorable status with respect to the primary outcome. NA denotes not applicable, and WGS whole-genome sequencing.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Among the participants who had a microbiologically unfavorable outcome, one in the rifapentine–moxifloxacin group had an isolate of recurrent <i>Mycobacterium tuberculosis</i> that showed phenotypic evidence of resistance to isoniazid plus rifampin but was susceptible to isoniazid and rifampin on line-probe molecular testing (WGS results were not available) and three in the rifapentine group had isolates of recurrent <i>M. tuberculosis</i> that showed evidence of resistance to isoniazid plus rifampin (WGS results were not available).</div></div></div></figcaption></a><figcaption><div class="caption">Primary Efficacy Analysis in the Microbiologically Eligible and the Assessable Populations.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2033400/asset/1c7f2a82-c984-4a8d-8a61-751da439eb3e/assets/images/large/nejmoa2033400_t3.jpg" height="2157" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Control<br>(N=825)</th><th class="txxx-borders">Rifapentine–Moxifloxacin<br>(N=846)</th><th class="txxx-borders">Rifapentine<br>(N=835)</th><th class="txxr-borders">Total<br>(N=2506)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary safety outcome</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Grade 3 or higher adverse event — no. (%)</td><td class="xxxx-borders">159 (19.3)</td><td class="xxxx-borders">159 (18.8)</td><td class="xxxx-borders">119 (14.3)</td><td class="xxxr-borders">437 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">−0.6 (−4.3 to 3.2)</td><td class="xxxx-borders shading">−5.1 (−8.7 to −1.5)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Secondary safety outcome</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Treatment-related grade 3 or higher adverse event — no. (%)</td><td class="xxxx-borders shading">81 (9.8)</td><td class="xxxx-borders shading">109 (12.9)</td><td class="xxxx-borders shading">64 (7.7)</td><td class="xxxr-borders shading">254 (10.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">NA</td><td class="xxxx-borders">3.0 (−0.0 to 6.1)</td><td class="xxxx-borders">−2.2 (−4.9 to 0.6)</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Other safety outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any serious adverse event — no. (%)</td><td class="xxxx-borders">56 (6.8)</td><td class="xxxx-borders">37 (4.4)</td><td class="xxxx-borders">39 (4.7)</td><td class="xxxr-borders">132 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death — no. (%)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">7 (0.8)</td><td class="xxxx-borders shading">3 (0.4)</td><td class="xxxx-borders shading">4 (0.5)</td><td class="xxxr-borders shading">14 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any adverse event resulting in discontinuation of assigned treatment — no. (%)<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7 (0.8)</td><td class="xxxx-borders">16 (1.9)</td><td class="xxxx-borders">11 (1.3)</td><td class="xxxr-borders">34 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any grade 3 or higher adverse event within 28 weeks after randomization</td><td class="xxxx-borders shading">159 (19.3)</td><td class="xxxx-borders shading">194 (22.9)</td><td class="xxxx-borders shading">138 (16.5)</td><td class="xxxr-borders shading">491 (19.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">ALT or AST level ≥5×ULN — no. (%)<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">24 (2.9)</td><td class="xxxx-borders">16 (1.9)</td><td class="xxxx-borders">13 (1.6)</td><td class="xxxr-borders">53 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">ALT or AST level ≥10×ULN — no. (%)</td><td class="xxxx-borders shading">9 (1.1)</td><td class="xxxx-borders shading">4 (0.5)</td><td class="xxxx-borders shading">5 (0.6)</td><td class="xxxr-borders shading">18 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Serum total bilirubin level ≥3×ULN — no. (%)<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">8 (1.0)</td><td class="xxxx-borders">28 (3.3)</td><td class="xxxx-borders">20 (2.4)</td><td class="xxxr-borders">56 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hy’s law criteria of ALT or AST level ≥3×ULN plus serum total bilirubin level ≥2×ULN — no. (%)</td><td class="xxxx-borders shading">7 (0.8)</td><td class="xxxx-borders shading">10 (1.2)</td><td class="xxxx-borders shading">8 (1.0)</td><td class="xxxr-borders shading">25 (1.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Premature discontinuation of assigned regimen in the microbiologically eligible population</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Discontinuation of assigned regimen for any reason — no./total no. (%)</td><td class="xxxx-borders shading">61/768 (7.9)</td><td class="xxxx-borders shading">55/791 (7.0)</td><td class="xxxx-borders shading">37/784 (4.7)</td><td class="xxxr-borders shading">153/2343 (6.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Percentage-point difference from control (95% CI)<a href="#core-t3fn3" role="doc-noteref">†</a></td><td class="xbxx-borders">NA</td><td class="xbxx-borders">−1.0 (−3.6 to 1.6)</td><td class="xbxx-borders">−3.3 (−5.7 to −0.9)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"><div class="label">*</div></a><div id="core-t3fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg">The safety analysis population included all the participants who had undergone randomization and received at least one dose of the assigned treatment. Safety was assessed during the on-treatment period (the time during which the participants were receiving the trial medications and up to 14 days after the last dose), unless otherwise specified. Adverse events were graded by the site investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events.<sup></sup></a><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="core-body-ref-r31-2" href-manipulated="true" aria-label="Reference 31" data-to-manipulate="false">31</a> ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and ULN upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The analysis was adjusted for the stratification factors of presence of cavitation on baseline chest radiography at baseline and HIV status.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">In the control group, death was due to paracoccidioides infection, sepsis, papillary thyroid cancer, central nervous system lesion, hemoptysis, or pulmonary embolism (in 1 participant each), and there was one unexplained death. In the rifapentine–moxifloxacin group, death was due to thrombotic thrombocytopenic purpura, congestive cardiac failure, or pulmonary tuberculosis (in 1 participant each). In the rifapentine group, death was due to alcohol poisoning, road traffic accident, or pulmonary embolism (in 1 participant each), and there was one unexplained death.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The assigned treatment was discontinued because of hepatitis (in 6 participants) or seizure (in 1 participant) in the control group; because of hepatitis (in 11 participants) or thrombocytopenia, QT prolongation, tendonitis, pruritus, or maculopapular rash (in 1 participant each) in the rifapentine–moxifloxacin group; and because of hepatitis (in 8 participants) or neutropenia, bacterial pneumonia, or drug reaction with eosinophilia and systemic symptoms (in 1 participant each) in the rifapentine group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">An ALT or AST level of at least 5×ULN corresponds with an adverse event of grade 3 or higher.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">A total bilirubin level of at least 3×ULN corresponds with an adverse event of grade 3 or higher.</div></div></div></figcaption><figcaption><div class="caption">Safety and Premature Discontinuation of Assigned Regimen.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033400_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2033400</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <em>Clin Infect Dis</em> 2016;63:853-867.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciw566" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27621353/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000386041100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Executive+summary%3A+official+American+Thoracic+Society%2FCenters+for+Disease+Control+and+Prevention%2FInfectious+Diseases+Society+of+America+clinical+practice+guidelines%3A+treatment+of+drug-susceptible+tuberculosis.&amp;publication_year=2016&amp;journal=Clin+Infect+Dis&amp;pages=853-867&amp;doi=10.1093%2Fcid%2Fciw566&amp;pmid=27621353" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing adverse drug effects and costs. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] weeks of once-daily rifampin and isoniazid. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] doses adjusted for body weight (Table S1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] was administered on an empty stomach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, April 2017 (<a href="https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/">https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+treatment+of+drug-susceptible+tuberculosis+and+patient+care%2C+2017+update&amp;publication_year=2017" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing adverse drug effects and costs. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] weeks of once-daily rifampin and isoniazid. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more — effective tuberculosis vaccines, drugs, and diagnostics. <em>Proc Natl Acad Sci U S A</em> 2009;106:13980-13985.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0901720106" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19666590/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269078700065" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiological+benefits+of+more+%E2%80%94+effective+tuberculosis+vaccines%2C+drugs%2C+and+diagnostics.&amp;publication_year=2009&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=13980-13985&amp;doi=10.1073%2Fpnas.0901720106&amp;pmid=19666590" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Bonnett LJ, Ken-Dror G, Koh GCKW, Davies GR. Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early-phase clinical trials. <em>Clin Infect Dis</em> 2017;65:46-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/cix247" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28402396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403459300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+the+efficacy+of+drug+regimens+for+pulmonary+tuberculosis%3A+meta-analysis+of+endpoints+in+early-phase+clinical+trials.&amp;publication_year=2017&amp;journal=Clin+Infect+Dis&amp;pages=46-54&amp;doi=10.1093%2Fcid%2Fcix247&amp;pmid=28402396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics–pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. <em>Antimicrob Agents Chemother</em> 2003;47:2118-2124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.47.7.2118-2124.2003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12821456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000183786700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics%E2%80%93pharmacodynamics+of+rifampin+in+an+aerosol+infection+model+of+tuberculosis.&amp;publication_year=2003&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2118-2124&amp;doi=10.1128%2FAAC.47.7.2118-2124.2003&amp;pmid=12821456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Svensson EM, Svensson RJ, Te Brake LHM, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. <em>Clin Infect Dis</em> 2018;67:34-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciy026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29917079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438446600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+potential+for+treatment+shortening+with+higher+rifampicin+doses%3A+relating+drug+exposure+to+treatment+response+in+patients+with+pulmonary+tuberculosis.&amp;publication_year=2018&amp;journal=Clin+Infect+Dis&amp;pages=34-41&amp;doi=10.1093%2Fcid%2Fciy026&amp;pmid=29917079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Savic RM, Weiner M, MacKenzie WR, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. <em>Clin Pharmacol Ther</em> 2017;102:321-331.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cpt.634" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28124478/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405679600035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+the+optimal+dose+of+rifapentine+for+pulmonary+tuberculosis%3A+exposure-response+relations+from+two+phase+II+clinical+trials.&amp;publication_year=2017&amp;journal=Clin+Pharmacol+Ther&amp;pages=321-331&amp;doi=10.1002%2Fcpt.634&amp;pmid=28124478" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduction in bacillary burden. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and moxifloxacin at a daily dose of 400 mg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] likely to be feasible in most settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. <em>Clin Pharmacokinet</em> 2001;40:327-341.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2165/00003088-200140050-00002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11432536/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000169347200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+pharmacokinetics+and+pharmacodynamics+of+the+rifamycin+antibacterials.&amp;publication_year=2001&amp;journal=Clin+Pharmacokinet&amp;pages=327-341&amp;doi=10.2165%2F00003088-200140050-00002&amp;pmid=11432536" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] facilitates the completion of treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the rifamycin used in each trial regimen. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Rodríguez JC, Ruiz M, López M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against mycobacterium tuberculosis. <em>Int J Antimicrob Agents</em> 2002;20:464-467.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0924-8579(02)00239-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12458143/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000179899100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+activity+of+moxifloxacin%2C+levofloxacin%2C+gatifloxacin+and+linezolid+against+mycobacterium+tuberculosis.&amp;publication_year=2002&amp;journal=Int+J+Antimicrob+Agents&amp;pages=464-467&amp;doi=10.1016%2FS0924-8579%2802%2900239-X&amp;pmid=12458143" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against mycobacterium tuberculosis. <em>Antimicrob Agents Chemother</em> 1998;42:2066-2069.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.42.8.2066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9687408/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075131800032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+vitro+and+in+vivo+activities+of+moxifloxacin+and+clinafloxacin+against+mycobacterium+tuberculosis.&amp;publication_year=1998&amp;journal=Antimicrob+Agents+Chemother&amp;pages=2066-2069&amp;doi=10.1128%2FAAC.42.8.2066&amp;pmid=9687408" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2004;169:421-426.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200310-1380OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14578218/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000188417800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin-containing+regimen+greatly+reduces+time+to+culture+conversion+in+murine+tuberculosis.&amp;publication_year=2004&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=421-426&amp;doi=10.1164%2Frccm.200310-1380OC&amp;pmid=14578218" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2004;170:1131-1134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200407-885OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15306535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000225076700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin-containing+regimens+of+reduced+duration+produce+a+stable+cure+in+murine+tuberculosis.&amp;publication_year=2004&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1131-1134&amp;doi=10.1164%2Frccm.200407-885OC&amp;pmid=15306535" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. <em>Am J Respir Crit Care Med</em> 2006;174:331-338.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200603-360OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16675781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239415200018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin+versus+ethambutol+in+the+first+2+months+of+treatment+for+pulmonary+tuberculosis.&amp;publication_year=2006&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=331-338&amp;doi=10.1164%2Frccm.200603-360OC&amp;pmid=16675781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. <em>Lancet</em> 2009;373:1183-1189.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(09)60333-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19345831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264940600032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Moxifloxacin+versus+ethambutol+in+the+initial+treatment+of+tuberculosis%3A+a+double-blind%2C+randomised%2C+controlled+phase+II+trial.&amp;publication_year=2009&amp;journal=Lancet&amp;pages=1183-1189&amp;doi=10.1016%2FS0140-6736%2809%2960333-0&amp;pmid=19345831" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. <em>Int J Tuberc Lung Dis</em> 2008;12:128-138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18230244/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252493800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+II+study+of+the+sterilising+activities+of+ofloxacin%2C+gatifloxacin+and+moxifloxacin+in+pulmonary+tuberculosis.&amp;publication_year=2008&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=128-138&amp;pmid=18230244" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. <em>N Engl J Med</em> 2014;371:1577-1587.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1407426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25196020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+moxifloxacin-based+regimens+for+drug-sensitive+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1577-1587&amp;doi=10.1056%2FNEJMoa1407426&amp;pmid=25196020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to shorten therapy to 4 months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and a two-sided type I error rate of 5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r40" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involved mostly hospitalized patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. <em>Am J Respir Crit Care Med</em> 2009;180:273-280.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200901-0078OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19406981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268696000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Substitution+of+moxifloxacin+for+isoniazid+during+intensive+phase+treatment+of+pulmonary+tuberculosis.&amp;publication_year=2009&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=273-280&amp;doi=10.1164%2Frccm.200901-0078OC&amp;pmid=19406981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Conde MB, Mello FCQ, Duarte RS, et al. A phase 2 randomized trial of a rifapentine plus moxifloxacin-based regimen for treatment of pulmonary tuberculosis. <em>PLoS One</em> 2016;11(5):e0154778-e0154778.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0154778" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27159505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376576700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2+randomized+trial+of+a+rifapentine+plus+moxifloxacin-based+regimen+for+treatment+of+pulmonary+tuberculosis.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0154778-e0154778&amp;doi=10.1371%2Fjournal.pone.0154778&amp;pmid=27159505" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Williams K, Tyagi S, et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. <em>Am J Respir Crit Care Med</em> 2005;172:1457-1462.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200507-1072OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16141439/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233697300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Weekly+moxifloxacin+and+rifapentine+is+more+active+than+the+Denver+regimen+in+murine+tuberculosis.&amp;publication_year=2005&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1457-1462&amp;doi=10.1164%2Frccm.200507-1072OC&amp;pmid=16141439" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? <em>Am J Respir Crit Care Med</em> 2008;178:989-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200807-1029OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18723432/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260611600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Isoniazid+or+moxifloxacin+in+rifapentine-based+regimens+for+experimental+tuberculosis%3F&amp;publication_year=2008&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=989-993&amp;doi=10.1164%2Frccm.200807-1029OC&amp;pmid=18723432" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. <em>PLoS Med</em> 2007;4(12):e344-e344.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.0040344" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18092886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000251874600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daily+dosing+of+rifapentine+cures+tuberculosis+in+three+months+or+less+in+the+murine+model.&amp;publication_year=2007&amp;journal=PLoS+Med&amp;pages=e344-e344&amp;doi=10.1371%2Fjournal.pmed.0040344&amp;pmid=18092886" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial. <em>Am J Respir Crit Care Med</em> 2015;191:333-343.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201410-1843OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25489785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348827000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daily+rifapentine+for+treatment+of+pulmonary+tuberculosis%3A+a+randomized%2C+dose-ranging+trial.&amp;publication_year=2015&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=333-343&amp;doi=10.1164%2Frccm.201410-1843OC&amp;pmid=25489785" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] time of completion of the intensive phase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and moxifloxacin at a daily dose of 400 mg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] was administered on an empty stomach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] with the result in a phase 2 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] likely to be feasible in most settings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Nahid P, Kurbatova EV, et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. <em>Contemp Clin Trials</em> 2020;90:105938-105938.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2020.105938" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31981713/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527917400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+or+without+moxifloxacin+for+shortening+treatment+of+pulmonary+tuberculosis%3A+study+protocol+for+TBTC+study+31%2FACTG+A5349+phase+3+clinical+trial.&amp;publication_year=2020&amp;journal=Contemp+Clin+Trials&amp;pages=105938-105938&amp;doi=10.1016%2Fj.cct.2020.105938&amp;pmid=31981713" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of the trial have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 1200 mg once daily, and efavirenz. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] according to 20 key elements (Table S16). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] might not be responding well to treatment. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. <em>Am J Respir Crit Care Med</em> 2011;184:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201103-0536OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21836139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296613900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multisite+assessment+of+the+quantitative+capabilities+of+the+Xpert+MTB%2FRIF+assay.&amp;publication_year=2011&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1076-1084&amp;doi=10.1164%2Frccm.201103-0536OC&amp;pmid=21836139" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. <em>J Clin Microbiol</em> 2011;49:2827-2831.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JCM.00138-11" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21653771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293221900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suitability+of+Xpert+MTB%2FRIF+and+genotype+MTBDRplus+for+patient+selection+for+a+tuberculosis+clinical+trial.&amp;publication_year=2011&amp;journal=J+Clin+Microbiol&amp;pages=2827-2831&amp;doi=10.1128%2FJCM.00138-11&amp;pmid=21653771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Soares JF, Wu CFJ. Some restricted randomization rules in sequential designs. <em>Commun Stat Theory Methods</em> 1983;12:2017-2034.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03610928308828586" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1983RD26100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Some+restricted+randomization+rules+in+sequential+designs.&amp;publication_year=1983&amp;journal=Commun+Stat+Theory+Methods&amp;pages=2017-2034&amp;doi=10.1080%2F03610928308828586" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. <em>Antimicrob Agents Chemother</em> 2010;54:3390-3394.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.00345-10" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20516273/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000279963300039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+four+different+meal+types+on+the+population+pharmacokinetics+of+single-dose+rifapentine+in+healthy+male+volunteers.&amp;publication_year=2010&amp;journal=Antimicrob+Agents+Chemother&amp;pages=3390-3394&amp;doi=10.1128%2FAAC.00345-10&amp;pmid=20516273" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] was administered on an empty stomach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the rifamycin used in each trial regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] improved in the presence of high-fat foods. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. <em>Chest</em> 1999;115:12-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.115.1.12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9925057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000078074200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+of+rifampin+under+fasting+conditions%2C+with+food%2C+and+with+antacids.&amp;publication_year=1999&amp;journal=Chest&amp;pages=12-18&amp;doi=10.1378%2Fchest.115.1.12&amp;pmid=9925057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Witney AA, Bateson ALE, Jindani A, et al. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. <em>BMC Med</em> 2017;15:71-71.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12916-017-0834-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28351427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397679000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+whole-genome+sequencing+to+distinguish+relapse+from+reinfection+in+a+completed+tuberculosis+clinical+trial.&amp;publication_year=2017&amp;journal=BMC+Med&amp;pages=71-71&amp;doi=10.1186%2Fs12916-017-0834-4&amp;pmid=28351427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Nunn AJ, Phillips PPJ, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. <em>Int J Tuberc Lung Dis</em> 2010;14:241-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20074418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274033300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Timing+of+relapse+in+short-course+chemotherapy+trials+for+tuberculosis.&amp;publication_year=2010&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=241-242&amp;pmid=20074418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">The common terminology criteria for adverse events, version 4.03. Bethesda, MD: National Institutes of Health, June 14, 2010 (<a href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r31-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+common+terminology+criteria+for+adverse+events%2C+version+4.03&amp;publication_year=2010" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r31-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Terminology Criteria for Adverse Events. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r31-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] Terminology Criteria for Adverse Events. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <em>N Engl J Med</em> 2014;371:1599-1608.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r32-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1314210&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+rifapentine+with+moxifloxacin+for+pulmonary+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1599-1608&amp;doi=10.1056%2FNEJMoa1314210&amp;pmid=25337749" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r32-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and a two-sided type I error rate of 5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r40" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] involved mostly hospitalized patients. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. <em>N Engl J Med</em> 2014;371:1588-1598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1315817&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25337748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343648500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+four-month+gatifloxacin-containing+regimen+for+treating+tuberculosis.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1588-1598&amp;doi=10.1056%2FNEJMoa1315817&amp;pmid=25337748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Mohamed K, Embleton A, Cuffe RL. Adjusting for covariates in non-inferiority studies with margins defined as risk differences. <em>Pharm Stat</em> 2011;10:461-466.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pst.520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21956950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295873100012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adjusting+for+covariates+in+non-inferiority+studies+with+margins+defined+as+risk+differences.&amp;publication_year=2011&amp;journal=Pharm+Stat&amp;pages=461-466&amp;doi=10.1002%2Fpst.520&amp;pmid=21956950" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Lumb R, Van Deun A, Bastian I, Fitz-Gerald M. <em>Laboratory diagnosis of tuberculosis by sputum microscopy: the handbook, global edition.</em> Adelaide, Australia: SA Pathology, 2013 (<a href="http://www.stoptb.org/wg/gli/assets/documents/TB%20MICROSCOPY%20HANDBOOK_FINAL.pdf">http://www.stoptb.org/wg/gli/assets/documents/TB%20MICROSCOPY%20HANDBOOK_FINAL.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Laboratory+diagnosis+of+tuberculosis+by+sputum+microscopy%3A+the+handbook%2C+global+edition.&amp;publication_year=2013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Reuben A. Hy’s law. <em>Hepatology</em> 2004;39:574-578.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.20081" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14768020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000220375600043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hy%E2%80%99s+law.&amp;publication_year=2004&amp;journal=Hepatology&amp;pages=574-578&amp;doi=10.1002%2Fhep.20081&amp;pmid=14768020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Fig. S9). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] levels or who met the criteria of Hy’s law. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. <em>Gut</em> 1972;13:366-371.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gut.13.5.366" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/5036092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972M829200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+rifampicin+on+liver+function+in+man.&amp;publication_year=1972&amp;journal=Gut&amp;pages=366-371&amp;doi=10.1136%2Fgut.13.5.366&amp;pmid=5036092" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. <em>Am J Respir Crit Care Med</em> 2006;174:935-952.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200510-1666ST" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17021358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241259000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+official+ATS+statement%3A+hepatotoxicity+of+antituberculosis+therapy.&amp;publication_year=2006&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=935-952&amp;doi=10.1164%2Frccm.200510-1666ST&amp;pmid=17021358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. <em>Clin Infect Dis</em> 2005;41:Suppl 2:S144-S157.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/428055" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15942881/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229891100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antimicrobial+safety%3A+focus+on+fluoroquinolones.&amp;publication_year=2005&amp;journal=Clin+Infect+Dis&amp;pages=S144-S157&amp;doi=10.1086%2F428055&amp;pmid=15942881" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Fox W. Whither short-course chemotherapy? <em>Br J Dis Chest</em> 1981;75:331-357.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0007-0971(81)90022-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7030377/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whither+short-course+chemotherapy%3F&amp;publication_year=1981&amp;journal=Br+J+Dis+Chest&amp;pages=331-357&amp;doi=10.1016%2F0007-0971%2881%2990022-X&amp;pmid=7030377" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="core-r41" class="citations"><div class="citation"><div class="citation-content">Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. <em>Curr Opin Pharmacol</em> 2018;42:7-15.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.coph.2018.05.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29885623/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450382700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Drug-resistant+tuberculosis%3A+challenges+and+opportunities+for+diagnosis+and+treatment.&amp;publication_year=2018&amp;journal=Curr+Opin+Pharmacol&amp;pages=7-15&amp;doi=10.1016%2Fj.coph.2018.05.013&amp;pmid=29885623" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="core-r42" class="citations"><div class="citation"><div class="citation-content">Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. <em>N Engl J Med</em> 2017;377:1043-1054.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_43_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033400&amp;key=10.1056%2FNEJMoa1614915&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28902596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410545200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+rapid+molecular+drug-susceptibility+test+for+tuberculosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1043-1054&amp;doi=10.1056%2FNEJMoa1614915&amp;pmid=28902596" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 16, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2114483" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Four-Month Rifapentine Regimens for Tuberculosis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 05, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2104499" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Shortening the Short Course of Tuberculosis Treatment</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">E.J. Rubin and V. Mizrahi</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/865656/division-chief-practice-lead-neurology-opportunity-in-the-beautiful-berkshires-of-western-ma-/?query=fjwp&amp;rid=886">Division Chief/ Practice Lead Neurology Opportunity in the Beautiful Berkshires of Western MA!</a></div></div><div class="nejm-widget_item"><div><span> Sayre, Pennsylvania</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887490/anesthesiology-phd-director-of-clinical-research-sayre-pa-/?query=fjwp&amp;rid=899">Anesthesiology/PhD - Director of Clinical Research (Sayre, PA)</a></div></div><div class="nejm-widget_item"><div><span> Philadelphia, Pennsylvania</span></div><div><span>Occupational Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887389/occupational-health-physician-jefferson-einstein-philadelphia/?query=fjwf&amp;rid=271428">Occupational Health Physician - Jefferson Einstein Philadelphia</a></div></div><div class="nejm-widget_item"><div><span> Middletown, New York</span></div><div><span>Cardiology / Interventional</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891446/physician-interventional-cardiologist/?query=fjwf&amp;rid=220874">Physician-Interventional Cardiologist</a></div></div><div class="nejm-widget_item"><div><span> Missouri</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886999/facility-medical-director-in-st-peters-mo/?query=fjwf&amp;rid=4552">Facility Medical Director in St. Peters, MO</a></div></div><div class="nejm-widget_item"><div><span> San Francisco, California</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885120/director-cardiovascular-research-institute/?query=fjws&amp;rid=121">Director, Cardiovascular Research Institute</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033400&amp;pubId=41290014&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d67cdc554fa432-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d67cdc554fa432-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d67cdc554fa432-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$154920574$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$154920574$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$154920574$--></div></div><div class="mlt-body"><!--?lit$154920574$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$154920574$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$154920574$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$154920574$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2308181?query=recirc_Semantic" target="_self">HIV-Associated Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$154920574$-->G. Meintjes and G. Maartens</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$154920574$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$154920574$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$154920574$-->Aug 22, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300054?query=recirc_Semantic" target="_self">Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$154920574$-->A. Jindani and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$154920574$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$154920574$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$154920574$-->Mar 10, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2200966?query=recirc_Semantic" target="_self">Childhood Tuberculosis — Time for Shorter and Differentiated Treatment</a></div><div class="mlt-article-authors"><!--?lit$154920574$-->M. Pai and H.J. Zar</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$154920574$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$154920574$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$154920574$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2400327?query=recirc_Semantic" target="_self">Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$154920574$-->L. Guglielmetti and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-practice" target="_self"><!--?lit$154920574$-->Clinical Practice</a> <span class="mlt-article-site-label"><!--?lit$154920574$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$154920574$-->Dec 09, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcp2108501?query=recirc_Semantic" target="_self">Latent Tuberculosis Infection</a></div><div class="mlt-article-authors"><!--?lit$154920574$-->M. Shah and S.E. Dorman</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2033400?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2033400" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033400.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2033400"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2100708" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Donanemab in Early Alzheimer’s Disease</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2028198" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f0.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/1a13f36b-26f4-4027-a8a6-75d141538758/assets/images/large/nejmoa2033400_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f1.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/6d56e303-6e87-4c44-9ea8-1166a19e1618/assets/images/large/nejmoa2033400_f1.jpg" height="2935" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">MTB denotes <i>Mycobacterium tuberculosis</i>.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033400_f2.jpg"><img src="/cms/10.1056/NEJMoa2033400/asset/f32abf9b-efd9-42ad-ba9a-f6785d479fd2/assets/images/large/nejmoa2033400_f2.jpg" height="3311" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Efficacy Analyses and Time to an Unfavorable Outcome.</div><div class="notes"><div role="doc-footnote">Panel A shows the results of the primary efficacy analysis in the microbiologically eligible and the assessable analysis populations and of the secondary analyses in the intention-to-treat and the per-protocol analysis populations (top, rifapentine–moxifloxacin regimen vs. control regimen; bottom, rifapentine regimen vs. control regimen). The noninferiority margin of 6.6 percentage points is designated by the dashed vertical line. Participants were classified as having an unfavorable outcome if they had <i>M. tuberculosis</i>–positive cultures from two sputum specimens obtained at or after week 17 without an intervening negative culture, died or were withdrawn from the trial or lost to follow-up during the treatment period, had an <i>M. tuberculosis</i>–positive culture when last seen, died from tuberculosis during the post-treatment follow-up, or received additional treatment for tuberculosis. The microbiologically eligible analysis population included all the participants except those who had no evidence of <i>M. tuberculosis</i>–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria; the participants with an outcome status that was not assessable were reclassified as having had an unfavorable outcome. The assessable analysis population included the participants in the microbiologically eligible population except those whose outcome status had been reclassified from not assessable to unfavorable. The per-protocol 75% and per-protocol 95% analysis populations included the participants in the assessable population, except those who did not complete 75% or 95% of the assigned treatment doses, respectively, unless the reason for inadequate treatment was death or bacteriologic treatment failure. Panel B shows the results for the time to unfavorable outcome for the microbiologically eligible population. Data were censored for the participants who could not be assessed. HIV denotes human immunodeficiency virus. The inset shows the same data on an expanded y axis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Participants at Baseline in the Microbiologically Eligible Population.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary Efficacy Analysis in the Microbiologically Eligible and the Assessable Populations.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Safety and Premature Discontinuation of Assigned Regimen.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/18" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 18</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 06, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028982" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Dexamethasone and Surgical-Site Infection</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.B. Corcoran and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 06, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028198" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.R. Lundgren and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 06, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2100708" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Donanemab in Early Alzheimer’s Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.A. Mintun and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2033400%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033400&amp;pubId=41290014&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2033400%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033400&amp;pubId=41290014&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id02873017760658866" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d67cdc554fa432-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d67cdc554fa432-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d67cdc554fa432-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d67cdc554fa432-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d67cdc554fa432-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d67cdc554fa432-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d67cdc554fa432-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d67cdc554fa432-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d67cdc554fa432-SJC"></script>
            
            
            
        
    




<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d67cdc554fa432-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d67cdc4c62a432',t:'MTc0OTUzMzU0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d67cdc4c62a432&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><hum-fvtmjrlxyvqr></hum-fvtmjrlxyvqr><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2033400?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-transactionid="rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" id="captureIFrame_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" target="captureIFrame_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="capture_screen"><input id="capture_signIn_js_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="js_version"><input id="capture_signIn_transactionId_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" type="hidden" class="capture_transactionId_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="capture_transactionId"><input id="capture_signIn_form_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="form"><input id="capture_signIn_flow_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="flow"><input id="capture_signIn_client_id_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="client_id"><input id="capture_signIn_redirect_uri_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="redirect_uri"><input id="capture_signIn_response_type_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="response_type"><input id="capture_signIn_flow_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="flow_version"><input id="capture_signIn_settings_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="settings_version"><input id="capture_signIn_locale_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="locale"><input id="capture_signIn_recaptcha_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_rwwwphf4v2wyda8ltdewzaubz7dq6cycd2tmr06p" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>